


# SCHEME CATALOGUE

External Quality  
Proficiency Testing Schemes




Clinical  
chemistry,  
Immune  
chemistry



25  
years



Haematology



Pathology

- **Quality**
- **Reliability**
- **Professional EQA Solution**
- **Patient Safety**



2022



**QualiCont Nonprofit Kft.**

**Independent, impartial and accredited  
proficiency testing provider  
organisation.**

**More than**

**25 years**

**in External Quality Assessment!**

## CONTENTS

GENERAL INFORMATION .....	6.
Colleagues .....	7.
QualiCont Experts .....	8.
Novelties and changes 2022.....	11.
Conditions for participating in surveys.....	12.
Shipment of samples.....	14.
Reporting results.....	15.
Evaluation .....	16.
SPECIAL SERVICES .....	19.
<b><i>Preanalytics</i></b> .....	<b>20.</b>
902. Preanalytical case study (electronical survey).....	20.
<b><i>Clinical chemistry / Immune chemistry</i></b> .....	<b>20.</b>
General chemistry .....	
1001. Clinical chemistry (wet) (+AST, +CRP) (A) (1 sample/survey, monthly scheme) .....	20.
100. Clinical chemistry (wet) (A) .....	20.
100eGFR. Clinical chemistry: eGFR (A) .....	21.
110. Neonatal bilirubin (A) .....	21.
111. Glucose - wet chemistry.....	21.
130. Faecal diagnostics: Calprotectin.....	21.
131. Faecal diagnostics: FOB (A) .....	21.
141. Electrophoresis .....	21.
151. Lipids/lipoproteins (A) .....	21.
Diabetes surveys .....	
145. Glycated proteins I. (A) .....	21.
146. Glycated proteins II. Fructosamine (A) .....	22.
Myocardial markers .....	
244. High sensitive CRP (A) .....	22.
760. Myocardial markers (A) .....	22.
Special surveys .....	
148.,1481. Abnormal hemoglobins ( $\beta$ -Thalassemia) .....	22.
1451+1481. HbA1C+Abnormal hemoglobins .....	22.
162. Haemoglobin fractions .....	23.
195. Therapeutic drugs (A) .....	23.
<b>1951. Therapeutic drugs (A) (1 sample/survey, monthly scheme)</b> .....	23.
196. Therapeutic drugs, hormones (A) .....	23.
196P. Complex immunoassay I. ....	23.
196PT. Complex immunoassay II. ....	24.
198. Hormones (A) .....	24.
198P. Hormones Plus .....	24.
199. Complex immunoassay III. ....	24.
241. Plasma proteins .....	25.
241P. Plasma protein Plus.....	25.
292. Tumour markers (A) .....	25.
293. Thyroid tumour markers (A).....	25.
294. Thyroid hormones (A).....	25.
295. Thyroid gland antibodies (A) .....	25.
298. Fertility, gravidity .....	26.
320. Procalcitonin (A) .....	26.
321. AST (A) .....	26.
322. CRP (A) .....	26.
323. Rheumatoid factor (A) .....	26.
325. CAR (CRP, AST, RF) .....	26.
700. Ethanol (A) .....	26.
780. Ethanol, Ammonia.....	26.
Urine chemistry .....	
171. Urine chemistry, qualitative (A) .....	27.
172. Urine sediment test (electronic) .....	27.
173. Urine chemistry, quantitative (A).....	27.
178. Narcotic drugs in human urine, qualitative and quantitative (A).....	27.

<b>POCT</b>	<b>27.</b>
147. Glycated proteins – POCT (A) .....	27.
161. Blood gas analysis (A).....	28.
286. Haemostasis (INR) – POCT (A) .....	28.
321P. Streptococcus, A antigen detection – POCT .....	28.
326. CRP – POCT (A).....	28.
762. Cardiac markers (incl. Troponin-I and -T).....	28.
800. Glucose (A) .....	28.
801. Ammonia .....	28.
<b>Haematology</b>	<b>29.</b>
211. Blood cell count (A).....	29.
613S. Blood cell count and WBC differentiation by automata (A).....	29.
212. Blood smear analysis (with Virtual Microscopy) .....	29.
215. Reticulocyte analysis I. (microscopy) .....	30.
216. Reticulocyte analysis II. (Flow cytometer) .....	30.
221., 222., 225., 226. Haemostasis I., II., V., VI. (A) .....	30.
231., 2311. Blood group serology (A) .....	31.
240., 2401. Sedimentation (A).....	31.
<b>Molecular biology</b>	<b>31.</b>
Molecular genetics	
730. Molecular genetics: Qualitative PCR technique .....	31.
740-747. Molecular genetics .....	31-32.
<b>Microbiology/Serology</b>	<b>32.</b>
Bacteriology, bacterial serology	
411., 4111. Bacteriology (A) .....	32.
413. Detection of bacteria from blood culture .....	32.
414. Detection of multi-resistant pathogens .....	33.
418. Detection of bacterial enteral pathogens .....	33.
419. Detection of bacterial respiratory pathogens .....	33.
334. Bacterial serology: <i>Helicobacter pylori</i> .....	33.
Virus serology	
344. Virus serology: Hepatitis B-I. (A) .....	33.
346. Virus serology: Hepatitis C (A).....	33.
3456. Virus serology: Hepatitis A, B, C+HIV .....	34.
351. Virus serology: Cytomegalovirus (A) .....	34.
352. Virus serology: Epstein-Barr virus (A) .....	34.
SARS-CoV-2 diagnostics	
3400. Virus nucleic acid determination: SARS-CoV-2 (A) .....	34.
3401. POCT: SARS-CoV-2 (A).....	34.
3402. Virus serology: SARS-CoV-2 (A) .....	35.
Mycology	
412.,4121. Mycology .....	35.
Infection serology	
311. Infection serology: Lues serology (A) .....	35.
3000. TORCHE.....	35.
3100.,31001. Complex infection serology .....	35.
Parasitology	
452. Parasite serology: <i>Toxoplasma gondii</i> .....	36.
<b>Autoimmune serology</b>	<b>36.</b>
251. Antinuclear antibodies (ANA, anti-ENA, anti-dsDNA) .....	36.
253. Liverspecific and aenemiaspecific antibodies .....	37.
257. Antibodies against ANCA/GBM .....	37.
265. Neurological Autoantibodies (Onko-neuronal) .....	37.
271. Coelikia-specific autoantibodies .....	37.
273. Rheumatoid factor + CCP .....	37.
275. Antiphospholipid-autoantibodies .....	38.

<b><i>Pathology</i></b>	<b><i>38.</i></b>
501. Histotechnology .....	38.
502. Immunohistochemistry .....	38.
503. Cervical cytology .....	39.
505. Diagnostic cytology (PILOT) .....	39.
<b><i>Index</i></b> .....	<b><i>40.</i></b>

## GENERAL INFORMATION

**QualiCont Nonprofit Kft.** is an **independent and impartial** Hungarian External Quality Assessment (**EQA**) **provider**.

It has been supporting the work carried out by in vitro diagnostic measuring places **for 25 years** by **organising** wide range of tests of **proficiency surveys** in order to maintain and improve the quality of professional work achieving increasing **patient safety** and a high level of **health protection** by **making healthcare diagnostics more reliable**.

### **QUALITY MANAGEMENT**

The Company has been **certified** since 2001 according to the ISO 9001 standard.

**Audited activities:** Planning, organization and management of proficiency testing (external quality assessment) and the related supporting services for in vitro medical diagnostic laboratories and investigators on other human and veterinary medicine.

**The certification document is available at [www.qualicont.com](http://www.qualicont.com).**

### **ACCREDITATION**

**QualiCont Nonprofit Kft. is a proficiency testing provider accredited by NAH** (National Accreditation Authority) **under registration number NAH-8-0002/2018**. According to **MSZ EN ISO/IEC standard 17043:2010**, the Company **received the accredited status in 2014**. **As of today, 52 of its proficiency testing schemes** have accredited status. All such schemes are accompanied by the letter (A) in related documentation.

Both the Accreditation Certificate and the Detailed scope of Accreditation are available on the QualiCont website: [www.qualicont.com](http://www.qualicont.com), as well as on the NAH website: [www.nah.gov.hu](http://www.nah.gov.hu).

The **proficiency tests organised by QualiCont** are internationally well-known and acknowledged schemes with approximately 3900 international participants thanks to the Distributors.

QualiCont sets the EQA schemes and prices on an **annual basis**, **but there is also an opportunity to apply during the year**.

### **ASSISTING AND SUPPORTING THE PROFESSIONAL WORK OF PARTICIPANTS**

You can receive **technical and professional assistance** regarding the implementation of proficiency testing by

- phone: +36 62 543-016
- email: [mail@qualicont.com](mailto:mail@qualicont.com)
- I-QC program.

Further **professional assistance is possible as follows:**

- consultations for small groups with **training purposes** scheduled in advance
- **one-on-one consulting opportunities** at prearranged times with pre-set conditions in order to solve selected issues, involving experts if necessary.
- once a year **accredited professional training session** (QualiCont Forum), so far available only in Hungarian language.

### **INTERNATIONAL RELATIONS**

QualiCont Kft. has been a member of

- **EQALM** (The European Organisation for External Quality Assurance Providers in Laboratory Medicine), since its foundation in 1996 and
- the EA-EUROLAB-EURACHEM's work group involved in external quality control accreditation since 2014,
- the **EEE PT WG** (EA-EUROLAB-EURACHEM's work group: 'Proficiency Testing in Accreditation').

## Colleagues

---

**Managing Director:** Dr. Erika Sárkány

**Head of Quality Management, Office manager:** Anita Komárominé Galisz

### Survey organisation

**Program-coordinator:** Virág Gyöngyösi

**Group of survey organisation/shipping:** Katalin Bartók  
Judit Besenyőiné Egri  
Dániel Danszky (microbiology)

**Evaluation Group:** Dr. Erika Sárkány  
Dr. Petra Magdolna Molnár  
Anita Galisz Komárominé  
Veronika Martonosi  
Dániel Danszky (microbiology)  
Imre Ocsovszki (pathology)

**Orders, Invoicing, Customer Relations:** Katalin Bartók  
Judit Egri Besenyőiné

**System Administrator:** Dr. Imre Ocsovszki

## Contact

---

**Office:** +36 62/543-016, +36 30/462-5864

**Head of Quality Management, Office manager:** +36 20/539-6864

**Program-coordinator:** +36 20/539-7143

**E-mail:** mail@qualicont.com

**Web:** www.qualicont.com

## QualiCont Experts

Our professional work at QualiCont is supported by our experts who are members of the Scientific Advisory Board. *President of the Scientific Advisory Board: Prof. Dr. László Dux*

### Preanalytics

902

#### Preanalytics Work Group

**Dr. Petra Magdolna Molnár**

mail@qualicont.com

**Dr. Anna V. Oláh**

volah.anna@qualicont.com

**Dr. Erika Sárkány**

mail@qualicont.com

**Dávid Sütő**

suto.david@qualicont.com

### Clinical chemistry/Immune chemistry

#### General chemistry

1001, 1001A, 100, 110, 111, 130, 131, 141, 151

**Dr. Gabriella Bekő**

beko.gabriella@qualicont.com

**Prof. Dr. László Góth**

goth.laszlo@qualicont.com

**Dr. Erika Sárkány**

mail@qualicont.com

100eGFR

**Dr. Andrea Siska**

siska.andrea@qualicont.com

#### Diabetes surveys

145, 1451, 146

**Dr. Erzsébet Nagy**

nagy.erzsebet@qualicont.com

**Dr. Emese Babarczy**

babarczy.emese@qualicont.com

#### Myocardiac markers

244, 760

**Dr. Gabriella Bekő**

beko.gabriella@qualicont.com

**Prof. Dr. László Góth**

goth.laszlo@qualicont.com

**Dr. Erika Sárkány**

mail@qualicont.com

### Special surveys

148, 1481, 1451+1481

**Dr. Zoltán András Mezei**

mezei.zoltan@qualicont.com

162, 241, 241P, 320, 700, 780

**Dr. Gabriella Bekő**

beko.gabriella@qualicont.com

**Prof. Dr. László Góth**

goth.laszlo@qualicont.com

**Dr. Erika Sárkány**

mail@qualicont.com

195, 1951, 196, 196P, 196PT, 198, 198P, 199, 292, 293, 294, 295

**Dr. Mária Telkes**

telkes.maria@qualicont.com

**Prof. Dr. Erzsébet Toldy**

toldy.erzsebet@qualicont.com

298

**Dr. Imre Földesi**

foldesi.imre@qualicont.com

321, 322, 323, 325

**Dr. Ágnes Hilbert**

hilbert.agnes@qualicont.com

### Urine chemistry

171, 172, 173, 178

**Erzsébet Buczkóné Berecz**

berecz.erzsebet@qualicont.com

### POCT surveys

147

**Dr. Erzsébet Nagy**

nagy.erzsebet@qualicont.com

**Dr. Emese Babarczy**

babarczy.emese@qualicont.com

161, 326

**Dr. Erika Sárkány**

mail@qualicont.com

286

**Dr. Gabriella Bekő**

beko.gabriella@qualicont.com

321P

**Prof. Dr. Edit Zsoldiné Urbán**

urban.edit@qualicont.com

762, 800, 801

**Dr. Éva Ajzner**

ajzner.eva@qualicont.com

**Hematology**

211, 212, 215, 216, 613S

**Dr. Katalin Horváth**

horvath.katalin@qualicont.com

212

**Dr. Szabolcs Modok**

modok.szabolcs@qualicont.com

**Prof. Dr. Gyula Varga**

varga.gyula@qualicont.com

221, 222, 225, 226, 240, 2401

**Dr. Gabriella Bekő**

beko.gabriella@qualicont.com

231, 2311

**Dr. Izabella Hoffer**

hoffer.izabella@qualicont.com

**Molecular biology****Molecular genetics**

730, 740, 741, 746, 747

**Dr. András Bors**

bors.andras@qualicont.com

**Clinical microbiology****Bacteriology, bacterial serology**

411, 4111, 413, 414, 418, 419, 334

**Prof. Dr. Edit Zsoldiné Urbán**

urban.edit@qualicont.com

**Mycology**

412, 4121

**Dr. Ilona Csányiné Dóczi**

doczi.ilona@qualicont.com

**Virus serology**

344, 346, 3456, 351, 352

**Dr. Gabriella Terhes**

terhes.gabriella@qualicont.com

**SARS-CoV-2 diagnostics**

3400, 3401, 3402

**Dr. Eszter Ujhelyi**

ujhelyi.eszter@qualicont.com

**Infection serology**

311

**Dr. Eszter Ostorházi**

ostorhazi.eszter@qualicont.com

3000, 3100, 31001

**Dr. Gabriella Terhes**

terhes.gabriella@qualicont.com

**Parasitology**

452

**Dr. József Danka**

danka.jozsef@qualicont.com

**Pathology**

501, 502

**Dr. Tibor Krenács**

krenacs.tibor@qualicont.com

503

**Cytodiagnostic section of Hungarian Society of Pathologists**

citologia@qualicont.com

**Autoimmune serology**

251, 253, 257, 265, 271, 273, 275

**Dr. Julianna Németh**

nemeth.julianna@qualicont.com

## I-QC Program

Based on the experience of the trial operation, taking into account the requests of the participants, **an expanded and constantly renewed Internet-based electronic customer service system** awaits the participants of the surveys, which is

- ✓ available on multiple types of IT devices
- ✓ offering complex services:
  - browser login, with a single point of access, find **everything in one place**
  - traceability of the whole survey process
- ✓ offering quick access to information:
  - results graphical interpretation (statistical demonstration)
  - quick identification of errors
- ✓ easy to handle.

Thanks to our online customer service system, you can **carry out all survey-related administrative tasks online**: contracting, ordering (which can be viewed and supplemented at any time), also **evaluations and graphic charts** (short- and long term), as well as **Certificates of Participation and Performance** can be viewed.

You can let us know about your proposals and remarks by sending us a message directly through our program.

### Our website's contents:

<b>I-QC program</b>	<p><i>Surveys</i> (reporting results)</p> <p><i>Assessment documents:</i></p> <ul style="list-style-type: none"> <li>- <u>Closed surveys</u>: pre-assessments: statistical demonstration and 'expected results/values'</li> <li>- <u>Evaluated surveys</u>: short and long term statistical demonstrations, evaluations compared to target values, certificates, graphic charts</li> </ul> <p><i>Contracts</i> (contracting)</p> <p><i>Orders</i></p> <p><i>Documents</i> (Evaluations, Manuals, User manual)</p>
<b>Pathology program</b>	Reporting results (in case of Cervical Cytology all parts are digital), Evaluations, Certificates
<b>News</b>	Important news, Up-to-date information about the launch of the current survey, submission deadline, status of evaluations
<b>About us</b>	About QualiCont, Quality Policy, Our Awards, Colleagues, Experts
<b>Certificates</b>	Accreditation Certificate, ISO Certificate
<b>Surveys</b>	General information (terms and conditions for participation in surveys, shipment of samples, reporting results, evaluations, certificates, special services, novelties, changes), Scheme Catalogue, List of parameters, Manuals, Unit conversation factors
<b>Events</b>	QualiCont Forum (at this moment only Hungarian language), Trainings
<b>Professional information</b>	Types of target values, acceptable ranges; Professional presentations and publications, Performance analysis
<b>Documents available for download</b>	Scheme catalogue, Calendar, Complaint sheet, Data protection and Data handling notice, Information Notice on the Possibility of Recourse to Conciliation Panels, Data Privacy Incident Report and other current documents
<b>Newsletters</b>	Newsletters sent by e-mail can be viewed here
<b>FAQ</b>	Frequently Asked Questions

**www.qualicont.com**

## NOVELTIES AND CHANGES 2022

---

### **I-QC NEXT**

In 2021, taking into account the suggestions and requests of the participants, **the following convenience features were developed** and introduced:

1. To assist the guide on the page, headings by year and year/survey have been added to the list of surveys under the Surveys and Evaluations menu options.
2. On the Evaluations tab in the list of schemes there are download arrows at the year, survey and next to the scheme names. By clicking on these the corresponding documents can be downloaded one by one or together in a ZIP file.  
The purpose of this development was to make downloading evaluation documents faster. From now on there is no need to open the schemes one by one.
3. At the Survey and Evaluation tabs **without opening a scheme** you can see new dates:
  - Dates of 'Deadline of evaluation publication'
  - Dates of publishing
4. Statistics:
  - If there are more than one result sheets for a scheme, the results can be selected separately at the short-term statistics (histogram, Youden-plot) and the long-term statistics as well and they can be seen on the result sheets separately and together.
  - If there are more than one result sheets for a scheme and the results were evaluated in different groups, these will be shown in different rows at the table below the statistics and different colours will indicate the different target value ranges.
  - If groupings are added, the settings affect the histogram(s) and the Youden-plot as well, thus the chosen group can be seen on the Youden-plot with different colours.

**Thank you for your suggestions and cooperation in creating these new features!**

### **SCHEMES AVAILABLE AGAIN:**

- 3000. TORCHE

**Any additional needs (e. g. frequency, sample number, content) beyond the advertised schemes should be written to us and we fulfill it if it is possible!**

### **CHANGES IN SCHEME FREQUENCY**

#### **Schemes what will change from yearly 4 to yearly 6 samples:**

- 700. Ethanol (A)

## CONDITIONS FOR PARTICIPATING IN SURVEYS

### How to apply?

You can apply to take part in the schemes announced by QualiCont Nonprofit Kft. in the **Scheme Catalogue** and in the **Order Form via the Distributors of QualiCont Kft. or contact the QualiCont office directly if there is no official Distributor of QualiCont in your country.**

In order to benefit from quick communication, please **give your email address** by all means!

### IMPORTANT!

**Most of the schemes can be ordered monthly with 1 sample, too (12 months x 1 sample). If there are at least 5 participants for the scheme in the required survey, the QualiCont tries to organise it by all means!**

### Step-by-Step Guide:

#### 1. Registering/Signing a contract

Registration is possible via the Distributor of QualiCont Kft. or contact the QualiCont office directly if there is no official Distributor of QualiCont in your country.


#### 2. Ordering external quality assessment schemes

**QualiCont offers 103 schemes in 2022.**

QualiCont only guarantees to fulfil full-year orders for 2022 if the application is received by the Company before the **31<sup>st</sup> of December 2021.**

**Although orders can be placed for single surveys during the year, as continuous participation in the external quality assessment is necessary for proper and responsible laboratory operation, registering for **participation in the full-year scheme is suggested.****

### Ordering process



Applications **received with a delay** and **orders submitted during the year** can only be handled by the Company during the following survey if the order is received no later than **1 month before the start of the scheduled date of the survey** and if sufficient controls sample is available.

#### 3. Choosing the documentation type (electronic or paper-based)

QualiCont **has switched to electronic communication** in its whole process of carrying out surveys (**Manuals, reporting results, evaluations, certificates**); however, as of 2022, the Company still allows both forms of communication (electronic and paper-based) under the condition that **paper-based communication is only provided if specifically requested and for a consideration.**

#### 4. Paying the participation fee

**Paying the participation fee to the Distributor of QualiCont Kft. or directly to QualiCont if there is no official Distributor in your country.**

The participation fee includes

- **the registration fee,**
- the **prices and packaging costs** of the survey samples,
- **electronically available** via I-QC:
  - computer assessment of one result per parameter and per sample (traditional, graphic and individual, long-term evaluations);
  - summarised evaluations;
  - **Certificates (Participation and Performance);**
  - **Annual Certificates of Efficiency** (annual, individual);
  - Final Report in the case of accredited schemes;
  - written evaluation, if needed;
- more data reporting through I-QC.

The participation fee does not include:

- fee of further assessments,
- paper-based documentation (result report, guide, evaluations, certificates),
- certified copies of certificates.

Detailed information about these services is available in the '**Special services**' part of the Scheme Catalogue. Please specify your needs in the Order Form's section of the same name.

**Cancelling surveys**

Cancellation of any survey already ordered can be accepted up to **one month before** the scheduled date of the **next of surveys** at the latest.

**Handling different needs**

If there is any special request, it is possible to choose a **transportation method different** from the one specified in the Scheme Catalogue under the condition that the Customer bears its cost.

**Failure to carry out surveys/  
handling changes during the year**

If **QualiCont fails to carry out a scheme partially or in its entirety** through the suppliers' fault, it **pays back** the cost of the service not provided. For the entirety of surveys and all its processes, including changes arising during the year (e.g. the content and implementation of the surveys is modified due to the replacement of a sample provider), **QualiCont takes responsibility and reserves the right to change.**

QualiCont informs the participants via its website or if necessary, through email or phone about possible changes in the content and implementation of surveys.

**The participants' code number**

QualiCont uses code numbers to identify the participants.

In the course of carrying out surveys, the code number should be used for all communication between the participants and the organiser.

**Processing confidential data**

QualiCont handles all data and information, including participants' data and the measurement results of the proficiency testing schemes, confidentially, which means that the participant's code number and any other information that is suitable for identification (name, address) cannot be included on any document accessible by any third party, e.g. summary accessible by other survey participants and other documents issued.

QualiCont hands any information about the surveys to any third party only with the permission of the affected participant.

We hereby inform our participants that QualiCont Nonprofit Kft. – **next to confidentiality** - is obliged to present the documents related to the proficiency tests to the accreditation and certification organizations.

## SHIPMENT OF SAMPLES

Carried out according to the schedule announced in the **Scheme Catalogue**, the **Order Form** and the **Calendar**.

Together with the **first sample shipment**, QualiCont sends out a **Manuals**, which contains the necessary information for the **storage** and **processing** of the survey samples. **Make sure you hold onto this!** Information necessary for **reporting results** is available electronically on **I-QC** at each result sheet or in a uniform document after logging into I-QC system by entering your individual code and clicking on the *Documents* menu. The Company provides paper-based communication only to those who have requested it. **Please check if the sample package corresponds to the delivery note!** If something is **missing from the package** or has arrived broken, **please notify the Distributor or QualiCont immediately** (before the submission deadline) to allow **corrections!**

### Survey samples

In each case, QualiCont provides such control samples to the participants that remain stable until the end of the survey, i.e. until the end of the answering of objections. Exceptions are those samples which, due to the nature of the component to be measured, must be analyzed within a short time. The stability of the survey test 'samples' cannot be interpreted in the case of the schemes performed with digital images or questionnaires.

### Damaged samples


QualiCont Kft. is unable to take responsibility for damages incurred **during shipment**, but – if possible – replaces the damaged samples free of charge.

If the sample damage occurs **at the participant** (it breaks or disappears there), QualiCont can only replace it for an additional fee!

### Quality complaints about the sample

**Please hold on to what remains of the samples** as prescribed to help resolve any potential complaints submitted after QualiCont has reported the evaluations.

If **quality complaints** arise about the samples (e.g. metrology issues, sample issues, uncertain matrix effect etc.), **return the sample to our address immediately!**



## REPORTING RESULTS

**Respecting submission deadlines** is a must for faster assessment!

### Reporting and assessment of results online:

You can report results by using a piece of online software called I-QC, which is available on **QualiCont Nonprofit Kft.'s website**. You can use the same software to **check evaluations** electronically.

**Participating measuring place** can use an **online interface** accessible via an individual code to report results, then check and download Individual and Summarised evaluations along with Certificates of Participation and Performance. In the I-QC software, each participant only has access to their own data.

Laboratories reporting results electronically will not receive **result reporting sheets and evaluations** on paper, but **can check and/or download and print it via I-QC**.

**Please do not submit your results on paper** if you have uploaded them electronically!

### Paper-based reporting and assessment:

If you wish to report your results **on paper** and require evaluations and certificates on paper, you will have to **request this specifically** in the Order Form, which **entails additional costs!**

**When reporting results, please refrain from using a fax machine; no faxed results will be accepted.**

### **ATTENTION!**

**The participants are responsible for all the information they report. The QualiCont takes responsibility for the processing the data!**

### Handling of results submitted with a delay:

#### 1. Handling of results submitted past the deadline, but before evaluations are issued

Survey results submitted past the reporting deadline, but before the issuance of evaluations may be accepted and eligible for assessment if the participant can provide a reason for its delayed submission and submits the measurement results. The request will be **examined by the Evaluation group and a decision will be made** accordingly.

## Processing and evaluation of results

### RECORDING OF RESULTS BY EQA ORGANISER

- entering electronically submitted results into QualiCont's data handling system
- entering results submitted on paper
- data verification

### EVALUATION

1. publishing **pre-assessments** (expected results and statistics) online
2. verifying and entering target values
3. comparing results to each other and to target values based on various algorithms
4. expert opinions

### ISSUING EVALUATIONS

1. issuing the evaluations and certificates of the **schemes announced in 6 surveys/year within 15 workdays** of the submission deadline
2. issuing evaluations and certificates for **all the other schemes no later than the next survey; evaluations** and certificates can be seen on the internet immediately after their issuance

### ANALYSING RESULTS

This is a must for quality improvement!  
Taking the necessary corrective measures in the measuring place.  
(submission of objections)

### 2. Management of results before evaluations are issued

QualiCont conducts data audits to ensure that the evaluation teams are as **homogeneous** as possible, given that administrative errors also lead to a misrepresentation of the overall performance of a measurement system and program. The data audit identifies incomplete reporting of results and robust discrepancies that are obvious, typically administrative in nature. It shall inform the laboratories concerned, giving them the opportunity to make the correction within the specified time limit.

### 3. Management of results submitted after evaluations have been issued

Measurement results submitted past the issuance of evaluations will only be accepted by QualiCont if the participant can provide credible documentation – measurement reports – to substantiate the results to be assessed. The documentation will be **examined by the Managing Director, who decides** whether it should be accepted.

## EVALUATION

---

You can find detailed information about the types of target values, the evaluation process and the way published performance evaluations are displayed in a publication called '**Evaluations**', which is available for participants as an electronic document in the I-QC system, accessible with their individual code in the *Documents* menu.

### Evaluation process:

**STATISTICS** become available immediately after the result reporting deadline. Pre-assessments are simple statistical analyses of the measurement results in the database at any given time, which enables quick detection and correction of any measurement errors.

Corrective action can be taken until no later than 1 week before issuance of the Final report.

In case of certain schemes, typically tests that have a serious impact on life, such as blood group serology, as well as certain microbiological tests, the expected results are published by the Company within two weeks of the result submission deadline.

In the course of the **evaluation, after entering the target values**, QualiCont Kft. uses its own proprietary software to compare measurement results amongst themselves and to target values and to make individual evaluations and various summaries.

In the case of accredited surveys, a document called Final Report contains information tracing back target values.

QualiCont determines **acceptable ranges** by taking into consideration professional expectations, expert recommendations and available international experience.

Interpretation of results is **facilitated by** various **graphic summaries**.

### Evaluation issuance deadline:

**The schemes announced in 12 and 6 surveys/year are assessed within 15 workdays** of the result submission deadline, with the results being issued and becoming available for participants in I-QC.

In case of **all the other schemes**, evaluations will be uploaded **no later than the sample shipment of the next survey**.

In the case of **pathological schemes**, the **evaluations** will be issued and uploaded into the Pathology scheme no later than the **sample shipment of the next survey**.

If, for any reason, a change other than the above occurs, the participants concerned will be informed.

### **The following assessments are issued for the participants:**

#### **Per survey:**

- **Individual evaluation** and **Summaries**,
- **Final Report** (in the case of all accredited surveys and many other schemes), in which the Company summarises all information regarding the proficiency testing.  
Schemes with a lower number of participants, regardless of whether they are accredited or not, come with a **summary table**, sorted by method and reagent for better comparability of results. E.g.: urine, drug schemes
- **Graphic – short term, long term – evaluations** (where applicable) can be consulted electronically and printed out using the I-QC system.
- Publication of **pre-assessments and expected results/values**
- **Summary report sheet (Individual numerical evaluation with summarised data) - New!**

**Evaluations are available via the online I-QC software!**

**QualiCont informs the participants of the issuance and availability of evaluations via email.**

#### **Evaluation conditions:**

The Company is only able to evaluate results that are returned to the office before the **deadline, validated within the online software I-QC** in the case of electronic reporting and **signed and stamped if submitted on paper.**

#### **Please take care to:**

- Provide additional information pertaining to measurement results accurately.
- Specify or select the right unit next to the results.

### **Providing additional data (method, device, reagent etc.):**

Providing additional data is important for correct evaluation. Absent this information, certain schemes (e.g. 196, 198, 292 etc.) cannot be evaluated, in cases where results and target values depend strictly on reagents, methods and the devices used.

#### **Assessment of a single result:**

If the participant only provides results for one sample, the provided result will be assessed by QualiCont, but if the participant does not provide a reason for the missing result when reporting, the Certificate of Performance will show the letter 'n' for the missing result even if the single result provided is accepted.

#### **Evaluation of a small number of measurement results:**

If the number of results submitted for a given measurement system is lower than 5 and the result is method/measurement system dependent and cannot be classified as belonging to any method/measurement system group and there are no target values determined on the basis of measurements by an expert laboratory commissioned by the manufacturer/supplier or QualiCont, we do not qualify the result.

## **Certificates**

---

QualiCont Nonprofit Kft. issues **five types of certificates:**

- **'Certificate of Participation'**, listing all parameters assigned to specific surveys where at least one result was reported by the participant.
- **'Certificate of Performance'** for each scheme in which the parameters are listed with 'y' and 'n' marks, depending on whether the result(s) of the parameter is (are) within the acceptable range.

The **Certificate of Performance** does not qualify the participant, it only gives information whether the result of the given parameter complied with the system of requirements set by the organizer or not.

- **'Annual Certificate of Efficiency'** is issued once a year by QualiCont following the publication of the evaluation of the last survey of the year, in which the percentage of acceptance of the evaluated measurement results for each scheme and parameter in the current year is communicated.
- **Summary annual performance certificate**
- **Summary annual performance certificate by parameter**

### Issuance of certificates:

QualiCont Nonprofit Kft. issues Certificates of performance and participation **with a time limit and exclusively to participants of the survey** after the evaluation of each survey.

**Certificates are published** electronically to **all measuring places** automatically, regardless of the type of (electronic or paper-based) service order.

If the service was ordered on paper, paper-based certificates will be issued on top of the electronic certificate.

If the service was ordered electronically, **paper-based certificates can be provided if requested for a consideration.**

**No subsequent certificate will be issued** for the same time period! Certified copies can be issued after payment of a processing fee!

For the following schemes, QualiCont currently **issues only Certificates of Participation:**

- 413. Detection of bacteria from blood culture
- 414. Detection of multi-resistant pathogens
- 418. Detection of bacterial enteral pathogens

- 419. Detection of bacterial respiratory pathogens
- 501-502. Pathology
- 503. Cervical cytology
- 902. Preanalytics

The authenticity of **electronically issued** certificates – downloadable via I-QC – is certified by the web address (electronic access route) of the original document found at the bottom of the page, which can be accessed using the measuring place's own code.

On paper-based certificates, authenticity is confirmed by an embossed stamp.

### Validity of the certificates:

The duration of validity of the Certificates of Participation and Performance **varies depending on the frequency of surveys:**

- for **once-yearly** schemes, the validity is for **14 months**,
- for **twice-yearly** schemes, it's **10 months**,
- for schemes **with 3 to 6 shipment per year**, it's for **6 months**,
- for schemes **with 12 shipment per year**, it's for **3 months**.

The dates of Certificates of Participation and Performance are identical, which is the result submission deadline for the proficiency testing in question.

## **Analysis of evaluations**

One of the most important elements of external quality assessment is the analysis of the assessments issued by the EQA organisation. This step is often skipped, even though **this is the basis of developing quality work** by

- exploring potential errors,
- taking corrective measures and
- implementing them.

**QualiCont runs checks before and after issuing evaluations! We ask that you do the same!**

## Corrective action, remarks, suggestions, objections

---

It is possible to make remarks and request corrective action relating to the evaluations and implementation of surveys.

Any claims and complaints are **only accepted** by QualiCont **in writing**, using the '**Complaint sheet**' intended for this purpose or **in any other informal written form** (via mail, email, customer service).

**Written objections to specific evaluations are accepted by the Company within 30 days of the email notification about the publication of the evaluation!**

QualiCont will respond to objections and remarks in writing. In the case of simple **administrative errors** (e.g. incorrect data entry, method/reagent clarification), the response deadline is **three weeks**.

If an **expert** or a reference laboratory needs to be involved, responding to an objection **takes longer**.

## SPECIAL SERVICES

---

In case the measuring place is not capable of determining the correct results in assessing patient test substances or the result obtained with the test substance is doubtful, QualiCont Kft. – with the help of an expert laboratory – offers a service which includes analysing test results and assessing the correct result and providing the correct assessment at the measuring place's request. The costs are determined on the basis of an individual agreement.

## Paper-based documentation

---

If you want to report results and get the evaluations and Certificates **on paper**, you must request it in the relevant part of the **Order Form for an additional fee!**

## Certified copies (of certificates)

---

Certified copies of certificates can be requested for an additional processing fee!

## Individual performance certificate

---

Issuing further performance certificates/ individual effectiveness analysis is possible at the request of participants for an additional fee.

## Further evaluations

---

If you want to have your sample tested and assessed at the same site of the same measuring place with different devices and methods, you can ask for further evaluation. For this, you only need to specify the code of the additional method/device on the order.

## Repeating a survey

---

If enough number of samples is available, it is possible to repeat a survey at a participant's request by sending in an additional sample and paying 70% of the full survey fee.

## Interlaboratory comparison tests

---

It is possible to organise interlaboratory comparison tests that are not available among QualiCont's proficiency tests. We draw up quotes and testing plans for specific requests.

# SURVEYS

## PREANALYTICS

### 902. Preanalytics case study (electronical survey)

	3.	9.
Start of the scheme (sample shipment)	08. 03.	13. 09.
Deadline of result reporting	25. 03.	28. 09.
Deadline of evaluation publication	12. 09.	03. 2023

#### Content of the scheme:

Evaluation of examples from the daily routine laboratory practice with the help of a questionnaire: identifying the possible analytical errors based on the written case or the laboratory measurement results.

#### Other information:

The **participation** is available for **free for every participant** that orders any of the QualiCont schemes.

## CLINICAL CHEMISTRY/ IMMUNE CHEMISTRY

### General chemistry

### 1001. Clinical chemistry (wet) (+AST, +CRP) (A) (1 sample/survey – monthly)

	1.	2.	3.	4.	5.	6.
Sample shipment	January 2022					
Deadline of result reporting	30. 01.	15. 02.	15. 03.	15. 04.	15. 05.	15. 06.
Deadline of evaluation publication	15. 02.	28. 02.	30. 03.	30. 04.	30. 05.	30. 06.
	7.	8.	9.	10.	11.	12.
Deadline of result reporting	15. 07.	15. 08.	15. 09.	15. 10.	15. 11.	15. 12.
Deadline of evaluation publication	30. 07.	30. 08.	30. 09.	30. 10.	30. 11.	30. 12.

#### Survey samples:

1 sample, 5 ml lyophilized serum each

#### Parameters:

**AST (O-Streptolysin)\*, Apolipoprotein A1 and B\***, Alpha-amylase, Alpha-HBDH, Albumin, Albumin (elpho), Alkaline phosphatase, Bilirubin (conjugate/direct), Bilirubin (total), Bicarbonate, Calcium, Chloride, Cholesterol, Cholinesterase, CK, Copper, Creatinine, **CRP\***, Gamma-globulin (elpho), Gamma-GT, GLDH, Glucose, GOT/ASAT, GPT/ALAT, HDL cholesterol, IgA, **IgE\***, IgG, IgM, Iron, Lactate, LDH, **LDL cholesterol\***, Lipase, Lithium, Magnesium, Osmolality, Pancreatic amylase, Phosphate (inorganic), Potassium, **Rheuma factor\***, Sodium, TIBC (Total Iron-Binding Capacity), Total protein, Transferrin, Triglycerides, Urea, Uric acid, **UIBC (Unsaturated Iron Binding Capacity)\*, Zinc\***

\*non accredited parameter

#### Other information: Order is possible only at least in 10 surveys!

The samples are sent once a year; in January.

### 100. Clinical chemistry (wet) (A)

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

#### Survey samples:

2 samples, 5 ml lyophilized serum each

#### Parameters:

Alpha-amylase, Alpha-HBDH, Albumin, Albumin (elpho), Alkaline phosphatase, Bilirubin (conjugate), Bilirubin (total), Bicarbonate, Calcium, Chloride, Cholesterol, Cholinesterase, CK, Copper, Creatinine, Gamma-globulins (elpho), Gamma-GT, Glucose, GOT/ASAT, GPT/ALAT, GLDH, HDL cholesterol, IgA, IgG, IgM, Iron, Lactate, LAP, LDH, Lipase, Lithium, Magnesium, Osmolality, Pancreatic amylase, Phosphate (inorganic), Potassium, Sodium, Total TIBC (Iron-Binding Capacity), Total protein, Transferrin, Triglycerides, Urea, Uric acid, **UIBC (Unsaturated Iron Binding Capacity)\***

\*non accredited parameter

It is possible to order this scheme monthly with 1 sample, too (12 months x 1 sample). Please contact your distributor for details.

**100eGFR. Clinical chemistry: eGFR (A)**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Content of the scheme:**

Calculating eGFR with the given creatinine values and case history.

Two cases are sent per survey.

**Other information:**

The **participation** is available for **free for every participant** that orders scheme 100. or **1001**. Clinical chemistry.

It is also **available** for those that do not participate in scheme **100. or 1001**. Clinical Chemistry, but only for extra cost.

**110. Neonatal bilirubin (A)**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 2 ml lyophilized serum each

**Parameters:** Bilirubin (total)

**111. Glucose – wet chemistry**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 5 ml lyophilized serum each

**Parameters:** Glucose

**130. Faecal diagnostics: Calprotectin**

	5.	11.
Start of the scheme (sample shipment)	17. 05.	08. 11.
Deadline of result reporting	01. 06.	23. 11.
Deadline of evaluation publication	07. 11.	05. 2023

**Survey samples:**

2 samples, 0.2 ml lyophilized faecal sample each

**Parameters:**

Calprotectin (quantitative and qualitative)

**Elastase (quantitative and qualitative)**

**131. Faecal diagnostics: FOB (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:** 2 liquid samples

**Parameters:**

Haemoglobin (quantitative and qualitative)

**141. Electrophoresis**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:** 2 samples, 5 ml lyophilized serum

**Parameters:** Albumin, Electrophoretic fractions:

Albumin, Alpha1-globulins, Alpha2-globulins,  $\beta$ -globulins, Gamma-globulins, Total protein

**151. Lipids/lipoproteins (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 3 ml lyophilized serum each

**Parameters:** Apolipoprotein A1,

Apolipoprotein B, Cholesterol, HDL- and LDL-cholesterol, Lp(a), Phospholipids, Triglycerides

**Diabetes surveys****145. Glycated proteins I. (A)**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 0.5 ml lyophilized haemolysates each

**Parameters:** HbA<sub>1c</sub>, HbA<sub>1c</sub>

It is possible to order this scheme monthly with 1 sample, too (12 months x 1 sample). Please contact your distributor for details.

### 146. Glycated proteins II. Fructosamine (A)

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

#### Survey samples:

2 samples, 1 ml lyophilized serum each

**Parameters:** Fructosamine

### Myocardial markers

### 244. High sensitive CRP (A)

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:** 2 samples, 1 ml plasma each

**Parameter:** High sensitive CRP

### 760. Myocardial markers (A)

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:** 2 samples, 3 ml lyophilized plasma or 1.5 ml liquid samples each

#### Parameters:

BNP, CK-MB (activity or mass), CK total, Homocysteine, Myoglobin, NT-pro BNP (N-terminal proBNP), Troponin-I, Troponin-T

#### Other information:

Troponin-I and Troponin-T can be measured from the samples by POCT devices, too!

### Special surveys

### 148. Abnormal haemoglobins ( $\beta$ -Thalassemia)

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

#### Survey samples:

2 samples, 0.2 ml lyophilized haemolysates each

**Parameters:** HbA<sub>2</sub>, HbF, HbS, HbC, interpretation

#### Aim and content of the scheme:

Determination (in %) of different haemoglobin types - abnormal haemoglobins - by HPLC instrument and interpretation of results.

### 1481. Abnormal haemoglobins ( $\beta$ -Thalassemia) (1 sample/survey)

	1.	2.	3.	4.	5.	6.
Sample shipment	January 2022					
Deadline of result reporting	30. 01.	15. 02.	15. 03.	15. 04.	15. 05.	15. 06.
Deadline of evaluation publication	15. 02.	28. 02.	30. 03.	30. 04.	30. 05.	30. 06.
	7.	8.	9.	10.	11.	12.
Deadline of result reporting	15. 07.	15. 08.	15. 09.	15. 10.	15. 11.	15. 12.
Deadline of evaluation publication	30. 07.	30. 08.	30. 09.	30. 10.	30. 11.	30. 12.

#### Survey samples:

1 sample 0.2 ml lyophilized haemolysate

**Parameters:** HbA<sub>2</sub>, HbF, HbS, HbC, interpretation

#### Aim and content of the scheme:

Determination (in %) of different haemoglobin types - abnormal haemoglobins - by HPLC instrument and interpretation of results.

### 1451+1481. HbA1C + Abnormal haemoglobins

	1.	2.	3.	4.	5.	6.
Sample shipment	January 2022					
Deadline of result reporting	30. 01.	15. 02.	15. 03.	15. 04.	15. 05.	15. 06.
Deadline of evaluation publication	15. 02.	28. 02.	30. 03.	30. 04.	30. 05.	30. 06.
	7.	8.	9.	10.	11.	12.
Deadline of result reporting	15. 07.	15. 08.	15. 09.	15. 10.	15. 11.	15. 12.
Deadline of evaluation publication	30. 07.	30. 08.	30. 09.	30. 10.	30. 11.	30. 12.

**Survey samples:** 2 samples, 0.5 ml + 0.2 ml lyophilized haemolysates each

#### Parameters:

HbA<sub>1c</sub>, HbA<sub>1c</sub>, HbA<sub>2</sub>, HbF, HbS, HbC, interpretation

#### Aim and content of the scheme:

Determination (in %) of different haemoglobin types - abnormal haemoglobins and interpretation of results.

**162. Haemoglobin fractions**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:** 2 samples, 1.2 ml liquid each

**Parameters:**

COHb fraction, MetHb fraction, O<sub>2</sub>Hb fraction, Total haemoglobin

**195. Therapeutic drugs (A)**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 5 ml lyophilized serum each

**Parameters:**

Amikacin, Caffeine, Carbamazepine, Cyclosporine, Digoxin, Ethosuximide, Gentamicin, Lithium, Methotrexate, Paracetamol, Phenobarbital, Phenytoin, Primidone, Salicylate, Theophylline, Tobramycin, Valproic acid, Vancomycine



New

**1951. Therapeutic drugs (A)  
(1 sample/survey)**

	1.	2.	3.	4.	5.	6.
Sample shipment	January 2022					
Deadline of result reporting	30. 01.	15. 02.	15. 03.	15. 04.	15. 05.	15. 06.
Deadline of evaluation publication	15. 02.	28. 02.	30. 03.	30. 04.	30. 05.	30. 06.
	7.	8.	9.	10.	11.	12.
	January 2022					
Deadline of result reporting	15. 07.	15. 08.	15. 09.	15. 10.	15. 11.	15. 12.
Deadline of evaluation publication	30. 07.	30. 08.	30. 09.	30. 10.	30. 11.	30. 12.

**Survey samples:**

1 samples, 5 ml lyophilized serum each

**Parameters:**

Amikacin, Carbamazepine, Digoxin, Gentamicin, Lithium, Phenobarbital, Phenytoin, Primidone, Salicylate, Theophylline, Tobramycin, Valproic acid, Vancomycine

**Other information:** Order is possible only at least in 10 surveys!

The samples are sent once a year; in January

**196. Therapeutic drugs, hormones (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 5 ml lyophilized each

**Parameters:**

11-Deoxycortisol, 17a-hydroxyprogesterone, 25-OH-Vitamin D, Acetaminophen, ACTH, Aldosterone, Amikacin,  $\beta$ -HCG, Calcitonin, Carbamazepine, Chloramphenicol, Cortisol, C-Peptide, Desipramine, DHEA, DHEA sulphate, Digoxin, Estradiol, Estriol (total, free), Ferritin, FSH, Gastrin, Gentamicin, HCG (total), HCG (total+ $\beta$ ), HGH, IgE, Imipramine, Insulin, LH, Lithium, Nortriptyline, Phenobarbital, Phenytoin, Primidone, Progesterone, Prolactin, Propranolol, PTH, Quinidine, Salicylate, Testosterone (free), Testosterone (total), Theophylline, Tobramycin, Valproic acid, Vancomycine, Vitamin B12

**196P. Complex immunoassay I.**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 5 ml lyophilized each

**Parameters:***Therapeutic drugs, hormones:*

11-Deoxycortisol, 17a-hydroxyprogesterone, 25-OH-Vitamin D, Acetaminophen, ACTH, Aldosterone, Amikacin,  $\beta$ -HCG, Calcitonin, Carbamazepine, Chloramphenicol, Cortisol, C-Peptide, Desipramine, DHEA, DHEA sulphate, Digoxin, Estradiol, Estriol (total, free), Ferritin, FSH, Gastrin, Gentamicin, HCG (total), HCG (total+ $\beta$ ), HGH, IgE, Imipramine, Insulin, LH, Lithium, Nortriptyline, Phenobarbital, Phenytoin, Primidone, Progesterone, Prolactin, Propranolol, PTH intact, PTH biointact, Quinidine, Salicylate, Testosterone (free), Testosterone (total), Theophylline, Tobramycin, Valproic acid, Vancomycine, Vitamin B12

*Thyroid hormones:*

FT3, FT4, T3, T4, TBG, TSH, T3-uptake, T-uptake

**196PT. Complex immunoassay II.**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 5 ml lyophilized each

**Parameters:**

*Therapeutic drugs, hormones:*

11-Deoxycortisol, 17 $\alpha$ -hydroxyprogesterone, 25-OH Vitamin D, Acetaminophen, ACTH, Aldosterone, Amikacin,  $\beta$ -HCG, Calcitonin, Carbamazepine, Chloramphenicol, Cortisol, C-Peptide, Desipramine, DHEA, DHEA sulphate, Digoxin, Estradiol, Estriol, Ferritin, FSH, Gastrin, Gentamicin, HCG (total), HCG (total+ $\beta$ ), HGH, IgE, Imipramine, Insulin, LH, Lithium, Nortriptyline, Phenobarbital, Phenytoin, Primidone, Progesterone, Prolactin, Propranolol, PTH intact, PTH biointact, Quinidine, Salicylate, Testosterone (free), Testosterone (total), Theophylline, Tobramycin, Valproic acid, Vancomycin, Vitamin B12,

*Thyroid hormones:*

T3, FT3, T4, FT4, T3-uptake, T-uptake, TBG, TSH

*Tumour markers:*

AFP, CEA, total PSA, free PSA

**198. Hormones (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 5 ml lyophilized each

**Parameters:**

11-Deoxycortisol, 17 $\alpha$ -hydroxyprogesterone, 25-OH-Vitamin D, ACTH, Aldosterone,  $\beta$ -HCG, Calcitonin, Cortisol, C-Peptide, DHEA, DHEA-sulphate, Estradiol, Estriol (total, free), FSH, Gastrin, HCG (total), HCG (total+ $\beta$ ), HGH, IgE, Insulin, LH, Progesterone, Prolactin, PTH intact, PTH biointact, Testosterone (free), Testosterone (total)

**198P. Hormones Plus**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 5 ml lyophilized each

**Parameters:**

*Hormones:*

11-Deoxycortisol, 17 $\alpha$ -hydroxyprogesterone, 25-OH-Vitamin D, ACTH, Aldosterone,  $\beta$ -HCG, Calcitonin, Cortisol, C-Peptide, DHEA, DHEA-sulphate, Estradiol, Estriol, FSH, Gastrin, HCG (total), HCG (total+ $\beta$ ), HGH, IgE, Insulin, LH, Progesterone, Prolactin, PTH intact, PTH biointact, Testosterone (free), Testosterone (total)

*Thyroid hormones:*

TSH, T3 (total), FT3, T4 (total), FT4, TBG, T3-uptake, T-uptake

**199. Complex immunoassay III.**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 3 ml lyophilized each

**Parameters:**

*Therapeutic drugs, hormones:*

17 $\alpha$ -hydroxyprogesterone, 25-OH-Vitamin D total, 1,25-OH-Vitamin D, Aldosterone, AMH, Androstenedione, B12-Vitamin (cobalamin), C-Peptide, DHEA-S, Digoxin, Ferritin, Folic acid, FSH, HCG (total), HGH, IgE (total), IgF-I, Insulin, Cortisol, LH, Methylmalonic acid, Estradiol, PAP (Prostatic Acid Phosphatase), Progesterone, Prolactin, PTH Intact, SHBG, Testosterone (total)

*Thyroid hormones and antibodies:*

Anti-TPO, Anti-TG, FT3, FT4, T3 total, T4 total, Thyroglobulin (TBG), TSH

*Tumour markers:*

alpha1-fetoprotein (AFP), CA 125, CA 15-3, CA 19-9, CEA, HE4, PSA,  $\beta$ 2-microglobulin,  $\beta$ -HCG, free PSA, total PSA, PSA complex

*Cardiac markers:*

CK-MB, CK-MB Mass, Homocystein, Nt-proBNP, Troponin-I, Troponin-T, Myoglobin

**Other information:**

It is possible to order this scheme monthly with 1 sample, too (12 months x 1 sample). Please contact your distributor for details.

**241. Plasma proteins**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 1 ml serum each

**Parameters:**

Albumin, Alpha-1-antitrypsin, Alpha-1-glycoprotein, Alpha-2-macroglobulin,  $\beta$ 2-mycroglobulin, C3 complement, C4 complement, Ceruloplasmin, CRP, Ferritin, Haptoglobin, Hemopexin, IgA, IgE, IgG, IgM, Prealbumin, Soluble transferrin receptor (sTfR), Transferrin

**241P. Plasma proteins Plus**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 1 ml plasma each

**Parameters:** Albumin, Alpha-1-antitrypsin, Alpha-1-glycoprotein,  $\beta$ 2-macroglobulin,  $\beta$ 2-mycroglobulin, C3 complement, C4 complement, Ceruloplasmin, CRP, Ferritin, Haptoglobin, Hemopexin, IgA, IgE, IgG, IgM, Prealbumin, Soluble transferrin receptor (sTfR), Transferrin, AST, RF

**Other information:**

It is possible to order this scheme monthly with 1 sample, too (12 months x 1 sample). Please contact your distributor for details.

**292. Tumour markers (A)**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 3 ml liquid serum each

**Parameters:** Alpha1-fetoprotein (AFP),  $\beta$ -HCG,  $\beta$ 2-microglobulin, CA 15-3, CA 19-9, CA 72-4, CA 125, CEA, Cyfra 21-1, HCG (total), HCG (total+ $\beta$ ), HE4, HER2, NSE, PSA (complex), PSA (free), PSA (total), ROMA, S100, SCC, Thyreoglobuline, TPA, TPS

**293. Thyroid tumour markers (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 2 ml lyophilized serum each

**Parameters:** 1,25-(OH)<sub>2</sub>-Vitamin D, 25-OH-Vitamin D, Anti-Thyreoglobulin (Anti-TG), Anti-thyroid peroxidase (Anti-TPO), C Peptide, Insulin, Insulin Like Growth Factor I (IGF-I), Osteocalcin, Procalcitonin, PTH (Parathyroid Hormone) Intact, PTH (Parathyroid Hormone) Biointact

**294. Thyroid hormones (A)**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 5 ml lyophilized serum each

**Parameters:**

Free T3, Free T4, Total T3, Total T4, TSH

**295. Thyroid gland antibodies (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, lyophilized plasma

**Parameters:**

Anti-thyreoglobulin (Anti-TG), Anti-thyroid peroxidase (Anti-TPO), TRAK/THYBIA, **TSI/TSAB\***

\*non accredited parameter

**298. Fertility, gravidity**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

Set 1: 2 samples, 2 ml lyophilized serum each

Set 2: 2 samples, 1 ml lyophilized serum each

**Parameters:**

Set 1: AFP, AMH (Anti-Müllerian hormone), hCG, PAPP-A, free  $\beta$ -chain HCG

Set 2: free Estriol\*

**\*Other information:**

For testing **free Estriol** plus separate samples are sent **for free, but can be ordered only together with Scheme 298!**

Please fill your claim in the Order form!

**320. Procalcitonin (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 2 ml lyophilized serum each

**Parameter:** Procalcitonin

**321. AST (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:** 2 samples, 1 ml serum each

**The content of the scheme:**

Antibodies against streptococcal antigens: Streptokinase, Streptodornase, O-Streptolysin

**322. CRP (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:** 2 samples, 1 ml serum each

**Parameter:** C-reactive protein

**323. Rheumatoid factor (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 1 ml serum each

**Parameter:**

Rheumatoid factor (RF)

**325. CAR**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 1 ml liquid serum each

**Parameters:**

C-reactive protein (CRP), Anti-streptolysin titer (AST), Rheumatoid factor (RF)

**700. Ethanol (A)**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 3 ml liquid serum each

**Parameter:** Ethanol

**780. Ethanol, Ammonia**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:** 2 samples, 3 ml serum or plasma liquid sample each

**Parameters:** Ethanol, Ammonia

## Urine chemistry

### 171. Urine chemistry, qualitative (A)

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:** 2 samples, 10 ml liquid urine each

#### Parameters:

Ascorbic acid, Bilirubin, Erythrocyte (RBC), Glucose, HCG, Ketone bodies, Leucocyte (WBC), Microscopic sediment examination, Nitrite, pH, Specific gravity, Total Protein, Urobilinogen

#### Additional information:

The test samples are basically intended for semi-quantitative urine chemistry with diagnostic test strips.

If two sets of samples are required for the determination, please order double amount!

### 172. Urine sediment test (electronic)

	3.	9.
Start of the scheme (sample shipment)	08. 03.	13. 09.
Deadline of result reporting	25. 03.	28. 09.
Deadline of evaluation publication	12. 09.	03. 2023

**Survey samples:** 2 digital images

#### Content of the survey:

Identification of urine sediment elements. Scheme is performed only electronically!

### 173. Urine chemistry, quantitative (A)

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

#### Survey samples:

2 samples, 5 ml lyophilized urine each

#### Parameters:

Alpha-amylase, Calcium, Chloride, Creatinine, Glucose, Magnesium, Microalbuminuria, Osmolality, Phosphate (inorganic), Potassium, Sodium, Total protein, Urea, Uric acid

### 178. Narcotic drugs in human urine, qualitative and quantitative (A)

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

#### Survey samples:

2 samples, 10 ml lyophilized urine each

#### Parameters:

*Amphetamines:* Amphetamine, Methamphetamine, MDMA (Ecstasy), Methylphenidate\*

*Barbiturates:* Barbiturate-Phenobarbital

*Benzodiazepines:* Benzodiazepin-Lorazepam

*Cannabinoids:* 11-nor-Delta-9-THC-COOH

*Cocaines:* Benzoyllecgonine, Cocaine\*

*Opiates/Opioids:*

Buprenorphine, EDDP, Methadone, Morphine, Phentanyl\*, Oxycodone\*, Tramadol\*, 6-acetylmorphine\*, LSD, Phencyclidine\*, Pregabalin\*, Tricyclic antidepressants (TCA)\*

\*non accredited parameter

## POCT

**When ordering the schemes please mark the type of the Instrument you measure the EQA samples with!**

### 147. Glycated proteins – POCT (A)

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:** 2 samples, 0.5 ml lyophilized haemolysates each

**Parameter:** HbA<sub>1c</sub>

**161. Blood gas analysis (A)**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 2.5 ml aqueous solution each

**Parameters:**

Calcium ion, Chloride, Glucose, Lactate, Magnesium\*, pCO<sub>2</sub>, pH, pO<sub>2</sub>, Potassium, Sodium

\*non accredited parameter

**286. Haemostasis (INR) – POCT (A)**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 lyophilized plasma samples

**Parameter:** INR

**Additional information:**

For each measuring system there is different kind of sample, so please give the used POCT system by all means!

**321P. Streptococcus, A antigen detection – POCT**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:** 2 samples, 1 ml liquid each

**Parameters:** Streptococcus A antigen

**326. CRP – POCT (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:** 2 samples, 1 ml serum each

**Parameter:** C-reactive protein

**762. Cardiac markers**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 1.5 ml liquid serum each

**Parameters:**

BNP, CK-MB (activity or MASS), D-Dimer, hs-CRP, Myoglobin, NT-Pro BNP, Troponin-I, Troponin-T

**800. Glucose (A)**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 1 ml liquid sample each

**Parameter:** Glucose

**Additional information:**

HemoCue and Lifescan systems are included!

**801. Ammonia**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 1 ml liquid each

**Parameter:** Ammonia

## HAEMATOLOGY

### 211. Blood cell count (A)

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:** 2 samples, 2 ml preserved, coagulation-inhibited blood

#### Parameters:

Erythrocytes, Haematocrit (centrifugated and electronic) Haemoglobin, Leucocyte, MCV, Platelet count, MCH, MCHC, MPV, RDW-CV\*, RDW-SD\*, Mentzer-index\*

\*non accredited parameter

**Additional information:** The survey sample is not recommended for *Abbott Cell Dyn (3200, 4000, Sapphire, Ruby)* devices.

### 613S. Blood cell count and WBC differentiation by automata (CBC and WBC diff.) (A)

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:** 2 samples, 2 ml preserved, coagulation-inhibited plasma-like fluid controls, which are suitable for every 3 or 5 part. diff. automated device to measure the basic parameters of blood cell count and testing leucocyte types.

**During ordering please indicate the type of the instrument: 3 or 5 part. diff.!**

#### Parameters:

Leucocytes, Leucocyte types (neu, eo, ba, mo, ly) in % and absolute value, mid cells (Eo, Baso, Mono) in % and absolute value, Erythrocytes, Haemoglobin, Haematocrit (automated), MCV, MCH, MCHC, Platelet count, MPV, RDW-CV, RDW-SV, Mentzer-index

WBC% is evaluated by instrument groups. It is possible to apply with the following instruments: *Diagon D-cell, Horiba Nexsus, Mindray, Orphee Mythic, Siemens Advia, Sysmex XT/XE/XS/XN*

**In case of Coulter and ABX the special samples mean extra cost for the participants.**

### 212. Blood smear analysis (with Virtual Microscopy)

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

#### Survey samples:

2 blood smear or digital pictures of a peripheral blood smear, short case history

#### The content of the scheme:

Blood cell differentiation of leukocytes in %, morphology of erythrocytes, leucocytes and platelets. Probable diagnosis.

#### Additional information:

This scheme basically runs online through the **Virtual Microscopy program**, developed by QualiCont. This software supports digital cell counting. This solution ensures the same quality of smear for each participant.

It is still possible to order smear, but only for extra cost.

The program requires the following hardware to run properly:

30 Mbit/s download speed,

10 Mbit/s upload speed,

Chrome 62+ (suggested), Firefox 56+, Safari 10+, Internet Explorer 11+, Edge 16+

System requirements in compliance with browser.

Remarks: However, the program may run by insufficient hardware conditions and by other browsers as well, but problems might occur in some functions. Before you start your own hardware I, please try to use it with your extant system and if you have any problem, please contact QualiCont for consultation, and thereafter carry out the necessary developments.

The images of smears can be still **viewed** on the Virtual microscope **after evaluation**.

**215. Reticulocyte analysis I.**

	3.	9.
Start of the scheme (sample shipment)	08. 03.	13. 09.
Deadline of result reporting	25. 03.	28. 09.
Deadline of evaluation publication	12. 09.	03. 2023

**Survey samples:**

2 blood smears for Microscopy analysis

**Parameters:**

reticulocyte count (% and absolute value)

**216. Reticulocyte analysis II.**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 whole blood sample for testing with instrument (Flow cytometer)

**Parameters:**

reticulocyte count (% and absolute value)

**221+222. Haemostasis I+II. (A)**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 1 ml lyophilized plasma each

**Parameters:**

Activated partial thromboplastin time (APTT), APTT rate, Fibrinogen, INR, Prothrombin time (PT), Thrombin time (TT), TI-rate

**Additional information:**

Combined order of scheme 221. and 222. enables favourable participation fee.

In this case 1 set of samples is included for the 2 schemes, in which the parameters of both schemes are involved. The evaluation of the 2 schemes is done separately in scheme 221. and 222.

**221. Haemostasis I. (A)**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 1 ml lyophilized plasma each

**Parameters:**

Activated partial thromboplastin time (APTT), APTT rate, INR, Prothrombin time (PT)

**222. Haemostasis II. (A)**

	1.	3.	5.	7.	9.	11.
Start of the scheme (sample shipment)	18. 01.	08. 03.	17. 05.	05. 07.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	25. 03.	01. 06.	19. 07.	28. 09.	23. 11.
Deadline of evaluation publication	16. 02.	14. 04.	23. 06.	09. 08.	18. 10.	14. 12.

**Survey samples:**

2 samples, 1 ml lyophilized plasma each

**Parameters:**

Fibrinogen, Thrombin time (TT), TI-rate

**225. Haemostasis V. (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 1 ml lyophilized plasma each

**Parameters:**

Antithrombin III., Protein C, Protein S

**226. Haemostasis VI. (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples 1.5 ml liquid sample, or lyophilized plasma each

**Parameter:** D-Dimer – quantitative**Additional information:**

The sample is suitable for measurements with POCT devices as well.

**231. Blood group serology (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	26. 09.	28. 11.
Deadline of result reporting	25. 03.	01. 06.	12. 10.	14. 12.
Deadline of evaluation publication	16. 05.	12. 09.	25. 11.	02. 2023

**Survey samples:**

2 samples, 6 ml fresh human blood clothed in coagulation each

**Parameters:** AB0 blood grouping, Rh system: D antigen, Rh-phenotyping, Irregular antibody screening, Direct Coombs-testing, Kell antigen, antibody identifying

**2311. Blood group serology (A)  
(1 sample/survey)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	26. 09.	28. 11.
Deadline of result reporting	25. 03.	01. 06.	12. 10.	14. 12.
Deadline of evaluation publication	16. 05.	12. 09.	25. 11.	02. 2023

**Survey samples:**

1 sample, 6 ml fresh human blood clothed in coagulation

**Parameters:** AB0 blood grouping, Rh system: D antigen, Rh-phenotyping, Irregular antibody screening, Direct Coombs-testing, Kell antigen, antibody identifying

**240. Sedimentation (A)**

	1.	5.	9.	11.
Start of the scheme (sample shipment)	18. 01.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:** 2 blood samples, 9 ml each

**Parameters:** Erythrocyte sedimentation

**2401. Sedimentation (A)  
(1 sample/survey)**

	1.	5.	9.	11.
Start of the scheme (sample shipment)	18. 01.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	01. 02.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:** 1 blood sample, 9 ml

**Parameters:** Erythrocyte sedimentation

**MOLECULAR BIOLOGY****Molecular genetics****730. Molecular genetics:  
Qualitative PCR technique**

	1.	5.	11.
Start of the scheme (sample shipment)	18. 01.	17. 05.	08. 11.
Deadline of result reporting	01. 02.	01. 06.	23. 11.
Deadline of evaluation publication	16. 05.	07. 11.	01. 2023

**Survey samples:**

1 sample, 0.5 ml

**Content of the scheme:**

For this analysis, primers are sent together with the necessary basic information for performing the amplification.

**Additional information:**

The amplification must be carried out using human DNA samples extracted in the participant's laboratory. The documentation of the raw data (e.g. copy of the gel photo and the determination of size of the received fragment(s)) have to be reported and will be evaluated!

**740. Molecular genetics:  
FV R534Q (Leiden) mutation detection**

	1.	5.	11.
Start of the scheme (sample shipment)	18. 01.	17. 05.	08. 11.
Deadline of result reporting	01. 02.	01. 06.	23. 11.
Deadline of evaluation publication	16. 05.	07. 11.	01. 2023

**Survey samples:**

3 samples, water solution of DNA isolated from human leukocytes

**The content of the scheme:**

Detection of the R534Q [rs6025] (Leiden) mutation in the coagulation Factor V gene.

### 741. Molecular genetics: Haemochromatosis HFE gene test (C282Y, H63D)

	1.	5.	11.
Start of the scheme (sample shipment)	18. 01.	17. 05.	08. 11.
Deadline of result reporting	01. 02.	01. 06.	23. 11.
Deadline of evaluation publication	16. 05.	07. 11.	01. 2023

#### Survey samples:

3 samples, water solution of DNA isolated from human leukocytes

#### The content of the scheme:

Detection of mutations C282Y [rs1800562], H63D [rs11799945] and in the HFE gene that predisposes for inherited hemochromatosis.

### 746. Molecular genetics: Prothrombin gene FII. G20210A variant detection

	1.	5.	11.
Start of the scheme (sample shipment)	18. 01.	17. 05.	08. 11.
Deadline of result reporting	01. 02.	01. 06.	23. 11.
Deadline of evaluation publication	16. 05.	07. 11.	01. 2023

#### Survey samples:

3 samples, water solution of DNA isolated from human leukocytes

#### The content of the scheme:

Analysis of the G20210A [rs1799963] variant in the coagulation Factor II (prothrombin) gene.

### 747. Molecular genetics: MTHFR gene (C677T) test

	1.	5.	11.
Start of the scheme (sample shipment)	18. 01.	17. 05.	08. 11.
Deadline of result reporting	01. 02.	01. 06.	23. 11.
Deadline of evaluation publication	16. 05.	07. 11.	01. 2023

#### Survey samples:

3 samples, water solution of DNA isolated from human leukocytes

#### The content of the scheme:

Analysis of the C677T (A226V) [rs1801133] frequent polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene.

## MICROBIOLOGY/SEROLOGY

### Bacteriology, bacterial serology

#### 411. Bacteriology (A)

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

#### Survey samples:

2 lyophilized bacterial cultures

**Task:** Identification of test strains and determination of antibiotic resistance sensitivity. Interpretation of report towards the clinician, information about additional (e.g. epidemiological) tasks.

#### 4111. Bacteriology (A) (1 sample/survey)

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

#### Survey samples:

1 lyophilized bacterial culture

**Task:** Identification of test strains and determination of antibiotic resistance sensitivity. Interpretation of report towards the clinician, information about additional (e.g. epidemiological) tasks.

#### 413. Detection of bacteria from blood culture

	5.	11.
Start of the scheme (sample shipment)	17. 05.	08. 11.
Deadline of result reporting	01. 06.	23. 11.
Deadline of evaluation publication	07. 11.	05. 2023

#### Survey samples:

2 lyophilized bacterial cultures

**Task:** Identification of test strains and determination of antibiotic resistance sensitivity. Interpretation of report towards the clinician, information about additional tasks.

**414. Detection of multiresistant pathogens**

	3.	9.
Start of the scheme (sample shipment)	08. 03.	13. 09.
Deadline of result reporting	25. 03.	28. 09.
Deadline of evaluation publication	12. 09.	03. 2023

**Survey samples:** 2 lyophilized bacterial cultures

**Task:** Identification of test strains and determination of antibiotic resistance sensitivity. Interpretation of report towards the clinician, information about additional tasks.

**418. Detection of bacterial enteral pathogens**

	5.	11.
Start of the scheme (sample shipment)	17. 05.	08. 11.
Deadline of result reporting	01. 06.	23. 11.
Deadline of evaluation publication	07. 11.	05. 2023

**Survey samples:** 1 lyophilized bacterial culture

**Task: Isolation and identification at species level of the enteric bacterial pathogen(s) responsible for the given enteric disease,** based on professional guidelines, as well as determination of the antibiotic susceptibility. Interpretation of report towards the clinician, information about additional (e.g. epidemiological) tasks. If no pathogenic bacteria are found in the sample, report what further tests you would ask for.

**419. Detection of bacterial respiratory pathogens**

	5.	11.
Start of the scheme (sample shipment)	17. 05.	08. 11.
Deadline of result reporting	01. 06.	23. 11.
Deadline of evaluation publication	07. 11.	05. 2023

**Survey samples:** 1 piece of sample

**Task: Isolation and identification at species level of the bacterial respiratory pathogen(s) from the given – occasionally lower and upper respiratory – samples, which can be responsible for the given disease, based on the anamnestic data,** as well as determination of the antibiotic susceptibility. Interpretation of report towards the clinician, information about additional (e.g. epidemiological) tasks. If no pathogenic bacteria are found in the sample, report what further tests you would ask for.

**334. Bacterial serology: *Helicobacter pylori***

	5.	11.
Start of the scheme (sample shipment)	17. 05.	08. 11.
Deadline of result reporting	01. 06.	23. 11.
Deadline of evaluation publication	07. 11.	05. 2023

**Survey samples:**

2 samples, 1 ml lyophilized each

**The content of the scheme:**

Detection of antibodies against *Helicobacter pylori* with EIA and other serological methods.

**Additional information:** Qualitative results are evaluated in the scheme.

**Virus serology****344. Virus serology: Hepatitis B-I. (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples, the content of the scheme:**

4 samples, 1 ml lyophilized serum each

2 samples: HbsAg,

2 samples: anti-HbsAg, anti-HBcAg

**Additional information:**

Qualitative results are evaluated in the scheme.

**346. Virus serology: Hepatitis C (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 2 ml lyophilized serum each

**The content of the scheme:**

Anti-HCV

**Additional information:**

Qualitative results are evaluated in the scheme.

**3456. Virus serology:  
Hepatitis A, B, C+HIV**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 2 ml lyophilized serum each

**The content of the scheme:**

Anti-HAV, HbsAb, HbcAb, HbeAb, Anti-HCV, Anti-HIV 1/2

**Additional information:**

The qualitative results are evaluated in the scheme.

**Other information:**

It is possible to order this scheme monthly with 1 sample, too (12 months x 1 sample). Please contact your distributor for details.

**351. Virus serology:  
Cytomegalovirus (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 1 ml lyophilized serum each

**The content of the scheme:**

Anti-CMV total antibody\*, Anti-CMV IgM, Anti-CMV IgG, CMV-IgG Avidity

\*non accredited parameter

**Additional information:**

Qualitative results are evaluated in the scheme.

**352. Virus serology:  
Epstein-Barr virus (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 1 ml lyophilized serum each

**The content of the scheme:**

Anti-EBNA IgG (total), Anti-EBNA IgM\*, Anti-EA IgG, Anti-EA IgM\*, Anti-VCA IgG, Anti-VCA IgM, Heterophilie antibodies (Paul Bunnel)

\*non accredited parameter

**Additional information:**

Qualitative results are evaluated in the scheme.

**SARS-CoV-2 diagnostics****3400. Virus nucleic acid determination:  
SARS-CoV-2 (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 1 ml respiratory VTM sample each

**The content of the scheme:**

PCR (Polymerase Chain Reaction) and applying other nucleic acid amplification techniques (NAT) for qualitative determination of SARS-CoV-2 virus.

**Individual and special delivery:** in a foam box with refrigerant, express delivery

**3401. POCT: SARS-CoV-2 (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 0.5 ml serum each

**The content of the scheme:**

SARS-CoV-2 IgG-, IgM and total immunoglobulin (IgG + IgM) determination with POCT devices, interpretation of results.

**Individual and special delivery:** in a foam box with refrigerant, express delivery

**3402. Virus serology: SARS-CoV-2 (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 1 ml serum each

**The content of the scheme:**

Applying serological techniques for quantitative and/or qualitative determination of IgG-, IgG-S, IgG-N, IgM, IgA and total immunoglobulin against SARS-CoV-2, interpretation of results.

**Individual and special delivery:** in a foam box with refrigerant, express delivery

**Micology****412. Micology (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, lyophilized or fungus culture on transport medium

**Content of the scheme:**

Identification of strains involved in fungus infection and determination of antimycotic sensitivity.

**4121. Micology (A)  
(1 sample/survey)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

1 sample, lyophilized or fungus culture on transport medium

**Content of the scheme:**

Identification of strains involved in fungus infection and determination of antimycotic sensitivity.

**Infection serology****311. Infection serology: Lues serology (A)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 0.4 ml serum each

**The content of the scheme:**

Antibodies against Treponema pallidum: FTA-Abs, ELISA, Immunoblot, TPHA, TPPA, CLMIA  
Antibodies against nontreponemal antigens: VDRL, RPR

**Additional information:**

Qualitative results are evaluated in the scheme. In case of RPR and VDRL titer is evaluated.

**3000. TORCHE**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 1 ml serum each

**The content of the scheme:**

CMV-IgG/IgM,  
HSV1/2-IgG/IgM,  
Rubeola-IgG/IgM,  
Toxo-IgG/IgM,  
EBV-VCA-IgG, EBV-IgM, EBV-EBNA-IgG

**Additional information:**

Qualitative results are evaluated in the scheme.

**3100. Complex Infection Serology**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 2-3 ml liquid serum each

**The content of the scheme:**

Cytomegalovirus (IgG and IgM, total antibody, avidity),  
 Epstein Barr Virus (Viral Capsid Antigen IgG),  
*Helicobacter pylori* (IgG),  
 Herpes Simplex Virus type 1 and 2 (IgG and IgM, total antibody), HSV1/2 (IgG and IgM),  
 Rubella Virus (IgG and IgM, total antibody),  
 Toxoplasma gondii (IgG and IgM, total antibody),  
 Treponema pallidum (IgG and RPR),  
 Varicella-zoster virus (IgG)

**Additional information:**

Qualitative results are evaluated in the scheme.

**31001. Complex Infection Serology (1 sample/survey)**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

1 sample, 2-3 ml liquid serum each

**The content of the scheme:**

Cytomegalovirus (IgG and IgM, total antibody, avidity),  
 Epstein Barr Virus (Viral Capsid Antigen IgG),  
*Helicobacter pylori* (IgG),  
 Herpes Simplex Virus type 1 and 2 (IgG and IgM, total antibody), HSV1/2 (IgG and IgM),  
 Rubella Virus (IgG and IgM, total antibody),  
 Toxoplasma gondii (IgG and IgM, total antibody),  
 Treponema pallidum (IgG and RPR),  
 Varicella-zoster virus (IgG)

**Additional information:** Qualitative results are evaluated in the scheme.

**Parasitology**

**452. Parasite serology: Toxoplasma gondii**

	3.	5.	9.	11.
Start of the scheme (sample shipment)	08. 03.	17. 05.	13. 09.	08. 11.
Deadline of result reporting	25. 03.	01. 06.	28. 09.	23. 11.
Deadline of evaluation publication	16. 05.	12. 09.	07. 11.	03. 2023

**Survey samples:**

2 samples, 1 ml lyophilized serum each

**The content of the scheme:**

Toxoplasmosis (IgG, IgM, IgA, polyvalent, avidity, interpretation)

**Additional information:**

Qualitative results are evaluated in the scheme.

**AUTOIMMUNE SEROLOGY**

**These schemes can be ordered only for the whole year!**

**251. Antinuclear antibodies (ANA, anti-ENA, anti-dsDNA)**

	5.	11.
Start of the scheme (sample shipment)	25. 05.	09. 11.
Deadline of result reporting	10. 06.	25. 11.
Deadline of evaluation publication	08. 11.	05. 2022

**Clinical applicability:**

Diagnostics and monitoring of systemic autoimmune diseases (ANA)

**Survey samples:** 2 samples, 0.5 ml lyophilized serum/plasma each

**The content of the scheme:**

Antinuclear antibody (ANA), ENA screen, ENA differentiation: U1-snRNP, Sm, Sm-RNP, SS-A (Ro52), SS-A (Ro60), SS-A (total), SS-B, Scl 70, Jo1, centromer (CENP B), Antibodies against ds-DNA

**Additional information:**

Qualitative results are evaluated in the scheme.

**253. Liverspecific autoantibodies**

	5.	11.
Start of the scheme (sample shipment)	17. 05.	08. 11.
Deadline of result reporting	01. 06.	23. 11.
Deadline of evaluation publication	07. 11.	05. 2023

**Clinical applicability:** Diagnostics and monitoring of autoimmune hepatic syndromes

**Survey samples:** 2 samples, 0.5 ml lyophilized serum/plasma each

**The content of the scheme:**

LKM (liver-kidney-microsomes) antibody, Antibodies against smooth muscles (SMA), mitochondrial (AMA)

**Additional information:**

Qualitative results are evaluated in the scheme.

**257. Antibodies against ANCA/GBM**

	5.	11.
Start of the scheme (sample shipment)	17. 05.	08. 11.
Deadline of result reporting	01. 06.	23. 11.
Deadline of evaluation publication	07. 11.	05. 2023

**Clinical applicability:** Diagnostics and monitoring of Vasculitis and Autoimmune Glomerulopathies

**Survey samples:**

Set 1:

2 samples, 0.5 ml lyophilized serum/plasma each

Set 2:

2 samples, 0.5 ml lyophilized serum/plasma each

**The content of the scheme:**

Set 1: Pr-3, MPO, cANCA (IIFT), pANCA (IIFT), atypical ANCA (IIFT), ANCA screen

Set 2: Antibodies against: glomerular basement membrane (GBM)

**Additional information:**

Qualitative results are evaluated in the scheme.

**265. Neurological Autoantibodies (Onko-neuronal)**

	5.	11.
Start of the scheme (sample shipment)	17. 05.	08. 11.
Deadline of result reporting	01. 06.	23. 11.
Deadline of evaluation publication	07. 11.	05. 2023

**Clinical applicability:** Diagnostics and monitoring of Paraneoplastic Neuropathies

**Survey samples:** 2 samples, 0.5 ml lyophilized serum/plasma each

**The content of the scheme:**

Onko-neural antibodies: Hu, Ri, Yo

**Additional information:**

Qualitative results are evaluated in the scheme.

**271. Coelikia-specific antibodies**

	5.	11.
Start of the scheme (sample shipment)	17. 05.	08. 11.
Deadline of result reporting	01. 06.	23. 11.
Deadline of evaluation publication	07. 11.	05. 2023

**Clinical applicability:**

Diagnostics and monitoring of Gluten-Sensitive Enteropathies

**Survey samples:** 2 samples, 0.5 ml lyophilized serum/plasma each

**Content of the scheme:**

Antibodies against:  
endomysium IgA, endomysium IgG,  
tissue transglutaminase IgA,  
tissue transglutaminase IgG,  
deamidated gliadin IgA,  
deamidated gliadin IgG

**Additional information:** Qualitative results are evaluated in the scheme.

**273. Rheumatoid factor + CCP**

	5.	11.
Start of the scheme (sample shipment)	17. 05.	08. 11.
Deadline of result reporting	01. 06.	23. 11.
Deadline of evaluation publication	07. 11.	05. 2023

**Clinical applicability:** Diagnostics and monitoring of Rheumatoid Arthritis

**Survey samples:** 2 samples, 0.5 ml lyophilized serum each

**Content of the scheme:**

rheumatoid factor,  
cyclic citrulline peptide (CCP)

**Additional information:**

Qualitative results are evaluated in the scheme.

**275. Antiphospholipid-autoantibodies**

	5.	11.
Start of the scheme (sample shipment)	17. 05.	08. 11.
Deadline of result reporting	01. 06.	23. 11.
Deadline of evaluation publication	07. 11.	05. 2023

**Clinical applicability:**

Diagnostics and monitoring of Antiphospholipid Syndrome

**Survey samples:** 2 samples, 0.5 ml lyophilized serum/plasma each

**The content of the scheme:**

Cardiolipin IgG and IgM,  
Cardiolipin screen (IgA/IgG/IgM)  
β2-glycoprotein IgG and IgM

**Additional information:**

Qualitative results are evaluated in the scheme.

---

## PATHOLOGY

---

**Unstained paraffin slides are sent to the participants.**

Task: Routin staining and detection of immunohistochemical marker molecules on the formaldehyde-fixed paraffin embedded sections distributed by QualiCont (2-2 unstained slides per test/per survey) and on slides of the similar tissue/tumour created in their own laboratory (in-house).

Reporting of results: The technical details of the stained sections and the methods are to be sent **electronically via Internet**.

**The evaluations and the Certificates are available electronically, too.**

Shipment of surveys:		3.	5.	9.	11.
501	Histotechnology	*	*	*	*
502	Immunohistochemistry	*	*	*	*
503	Cervical cytology	*	*	*	*

**501. Histotechnology**

The following slides are sent in each survey:

**HT/01 – Required sample in every survey**

Haematoxylin-eosin stain – **in-house**  
(Slide taken from the archive, registered on the number given by the organiser.)

**HT/02 – Slides provided by QualiCont in every survey**

Haematoxylin-eosin stain – **QualiCont**  
(Slide sent by the organiser.)

**HT/03 – Slides provided by QualiCont, various stains in every survey**

Special-stain – **QualiCont**

(1 from the list below)

- PAS
- Reticulin
- Elastic fibers
- Trichrome
- Amyloid
- Gram
- Giemsa
- Berlin-blue
- Ziehl-Neelsen
- Grocott

**502. Immunohistochemistry**

The following slides are sent in each survey:

**IHC/1**

**Repeated marker asked usually through 4 consecutive surveys**

Immunohistochemical reaction – **QualiCont**  
(Slide sent by the organiser.)

**IHC/2**

**Repeated marker asked usually through 4 consecutive surveys**

Immunohistochemical reaction – **In-house**  
(Own slide.)

**IHC/1-2:** (1 from the list below)

- Epithelial-marker
- Muscle-marker
- Endothelial-marker
- Leukocyte-marker
- Proliferation marker
- Hormone receptor (ER)
- Her-2 onkoprotein

**IHC/3 – Various markers by QualiCont in every survey**

Immunohistochemical reaction – **QualiCont**  
(Slide sent by the organiser.)

**IHC/4 – Various markers by QualiCont in every survey**

Immunohistochemical reaction – **In-house**  
(Own slide.)

**IHC/3-4:** (1 from the list above or below)

Immunohistochemical reaction - **QualiCont**

- Hormone receptor (PgR)
- B-lymphocyt
- T-lymphocyt
- Hodgkin-lymphoma
- Prostate-epithelial marker
- Melanoma-marker
- Endocrine marker
- Mesothelioma-marker

**Evaluation of slides:**

Four independent assessors using a consultation microscope evaluate the slides without influencing each other.

Score: 1-5 (*not acceptable – excellent*)

In case of 3 or lower score, critical remark is given, which refers to the nature of the error, or its probable cause.

Archiving: database management program

Processing: technical details of staining methods, evaluation data, remarks

Feedback: evaluation sheets, diagrams, statistical analysis

**503. Cervical cytology**

The scheme consists of 2 parts:

1.) Technical part: Preparing a smear from oral mucosa with spatula or brush and staining of it according to Papanicolaou in the lab of the participant.

2.) Diagnostic quality control:

Virtual images /5 pieces per survey/ of conventional Pap smear samples. The samples are stained by Papanicolaou selected from routine cytological materials (healthy and pathological) based on the evaluation of Bethesda system. The scheme runs on the Internet-based program of the QualiCont. All the smears are available for the participants only digitally.

For this scheme Certificate of Participation is issued by QualiCont.

**505. Diagnostic cytology (PILOT)**

5 Giemsa or HE stained slides are sent each survey on the field of diagnostic cytology (thyroid, urine, breast etc.)

The evaluations of the routine cytological cases from healthy and pathological slides are performed through the QualiCont online „Pathology software“ according to the topical finding system.

All of the slides are available only in digital format.

All participants receive a certificate of participation by QualiCont.

**500. Histotechnology and Immunohistochemistry together**

Combined order of the schemes enables favourable participation fee.

**504. Histotechnology, Immunohistochemistry and Cervical cytology together**

Combined order of the schemes enables favourable participation fee.

## I N D E X

<i><b>Analytes</b></i>	<i><b>Scheme no.</b></i>	<i><b>Page</b></i>
1,25-(OH) <sub>2</sub> -Vitamin D	199; 293	24; 25.
11-Deoxycortisol	196, 196P; 196PT, 198, 198P	23; 24.
11-nor-Delta-9-THC-COOH	178	27.
17 $\alpha$ -hydroxyprogesterone	196, 196P; 196PT, 198, 198P, 199	23; 24.
25-OH-Vitamin D	196, 196P; 196PT, 198, 198P, 199	23; 24.
"	293	25.
6-acetylmorphine	178	27.
<b>AB0</b> blood grouping	231, 2311	31.
Acetaminophen	196, 196P; 196PT	23; 24.
ACTH	196, 196P; 196PT, 198, 198P	23; 24.
Activated partial thromboplastin time (APTT)	221	30.
AFP	298	26.
Albumin	1001, 100; 141; 241, 241P	20; 21; 25.
Albumin (elpho)	1001, 100; 141	20; 21.
Aldosterone	196, 196P; 196PT, 198, 198P, 199	23; 24.
Alkaline phosphatase	1001, 100	20.
Alpha1-antitrypsin	241, 241P	25.
Alpha1-fetoprotein (AFP)	196PT, 199; 292	24; 25.
Alpha1-globulin	141	21.
Alpha1-glycoprotein	241, 241P	25.
Alpha2-globulin	141	21.
Alpha2-macroglobulin	241	25.
Alpha-amylase	1001, 100; 173	20; 27.
Alpha-HBDH	100, 1001	20.
AMH (Anti-Müllerian hormone)	199; 298	24; 26.
Amikacin	195, <b>1951</b> , 196, 196P; 196PT	23; 24.
Ammonia	780; 801	26; 28.
Amphetamine	178	27.
ANA	251	36.
ANA (IgG) – IIFT	251	36.
ANA (IgG/A/M) – IIFT	251	36.
ANCA screen	257	37.
Androstenedione	199	24.
Antibody identifying	231, 2311	31.
Antibody against Rubella virus (IgG and IgM)	3100, 31001	35.
Anti-CMV (IgG, IgM)	351; 3100, 31001	34; 35.
Anti-CMV total antibody	351	34.
Anti-EA IgG	352	34.
Anti-EA IgM	352	34.
Anti-EBNA IgG	352	34.
Anti-EBNA IgM	352	34.

<b>Analytes</b>	<b>Scheme no.</b>	<b>Page</b>
Anti-EBV	352	34.
Anti-HAV	3456	34.
Anti-HBc total (IgM+IgG)	344	33.
Anti-HbsAg	344	33.
Anti-HCV	346; 3456	33; 34.
Anti-HSV-1 – IgM, IgG	3100, 31001	35.
Anti-HSV-2 – IgM, IgG	3100, 31001	35.
Anti-Müllerian hormone (AMH)	<b>298</b>	26.
Anti-TG (Anti-thyreoglobulin)	293, 295	25.
Antithrombin III.	225	30.
Anti-thyreoglobulin (Anti-TG)	199; 293, 295	24; 25.
Anti-thyroid peroxidase (Anti-TPO)	199; 293, 295	24; 25.
Anti-TPO (Anti-thyroid peroxidase)	199; 293, 295	24; 25.
Anti-VCA (IgG, IgM)	352	34.
Apolipoprotein A1, B	151; 1001	21; 20.
APTT rate	221	30.
Ascorbic acid	171	27.
AST	1001; 241P; 325	20; 25; 26.
Atypical ANCA (IIFT)	257	37.
<b>Bacteriology – identification of test strains</b>	411; 418, 419	32; 33.
Bacterium in the sediment	171, 172	27.
Barbiturate-Phenobarbital	178	27.
Benzodiazepin-Lorazepam	178	27.
Benzoyllecgonine	178	27.
Bicarbonate	1001, 100	20.
Bilirubin (conjugate)	1001, 100	20.
Bilirubin (total)	1001, 100; 110; 171	20; 21; 27.
Bilirubin (unconjugate)	100	20.
Blood cell Differentiation of leukocytes in %	212	29.
BNP	760; 762	22; 28.
Buprenorphine	178	27.
<b>β-HCG</b>	196, 196P; 196PT, 198, 198P, 199; 292	23; 24; 25.
β-globulin	141	21.
β2-glycoprotein (IgM, IgG) antibodies	275	38.
β2-macroglobulin	241P	25.
β2-microglobulin	199; 241, 241P, 292	24; 25.
<b>C3 complement</b>	241, 241P	25.
<b>C4 complement</b>	241, 241P	25.
CA 125	199; 292	24; 25.
CA 15-3	199; 292	24; 25.
CA 19-9	199; 292	24; 25.
CA 72-4	292	25.
Caffeine	195	23.

<i><b>Analytes</b></i>	<i><b>Scheme no.</b></i>	<i><b>Page</b></i>
Calcitonin	196, 196P; 196PT, 198, 198P	23; 24.
Calcium	1001, 100; 173	20; 27.
Calcium ion	161	28.
Calprotectin	<b>130</b>	21.
cANCA (IIFT)	<b>257</b>	37.
Carbamazepine	195, <b>1951</b> , 196, 196P; 196PT	23; 24.
Cardiolipin (IgM, IgG) antibodies against	275	38.
CEA	196PT, 199; 292	24; 25.
Centromer (CENP B)	251	37.
Ceruloplasmin	241, 241P	25.
Chloramphenicol	196, 196P; 196PT	23; 24.
Chloride	1001, 100; 161; 173	20; 28; 27.
Cholesterol (Total)	1001, 100; 151	20; 21.
Cholinesterase (ChE)	1001, 100	20.
CK	1001, 100; 760	20; 22.
CK-MB	199; 760; 762	24; 22; 28.
CK-MB Mass	199	24.
CK Total	760	22.
CLMIA	311	35.
Cobalamine (Vitamin B12)	196; 199	23; 24.
Cocaine (Benzoyllecgonine)	178	27.
COHb fraction	162	23.
Copper	1001, 100	20.
Cortisol	196, 196P; 196PT, 198, 198P, 199	23; 24.
C-Peptide	196, 196P; 196PT, 198, 198P, 199	23; 24.
"	293	25.
Creatinine	1001, 100; 173	20; 27.
CRP (C-reactive protein)	1001; 244; 241, 241P; 322, 325; 762	20; 22; 25; 26; 28.
"	326, 762	28.
Crystals in the sediment	171, 172	27.
Cyclic citrullinated peptide antibody (anti-CCP)	273	37.
Cyclosporine	195	23.
Cyfra 21-1	292	25.
Cylinders in the sediment	171, 172	27.
Cytomegalovirus (IgG and IgM)	351; <b>3000</b> , 3100, 31001	34; 35.
<b>D</b> -Dimer	762; 226	28; 30.
Deamidated gliadin IgA, IgG antibodies against	271	37.
Desipramine	196, 196P; 196PT	23; 24.
Detection of bacterial enteral pathogens	418	33.
Detection of bacterial respiratory pathogens	419	33.
DFS70/LEDGF	251	36.
DHEA	196, 196P; 196PT, 198, 198P	23; 24.
DHEA sulphate	196, 196P; 196PT, 198, 198P, 199	23; 24.
Digoxin	195, <b>1951</b> , 196, 196P; 196PT, 199	23; 24.

<b>Analytes</b>	<b>Scheme no.</b>	<b>Page</b>
Direct Coombs-testing	231, 2311	31.
Ds-DNA antibody	251	36.
<b>EBV-EBNA-IgG</b>	352	34.
EBV-VCA-IgG	352	34.
EDDP	178	27.
eGFR	100eGFR	21.
<b>Elastase (quantitative and qualitative)</b>	<b>130</b>	<b>21.</b>
ELISA	311	35.
ENA differentiation	251	36.
Endomysium IgA, IgG antibodies against	271	37.
Epstein Barr Virus antibody against (IgG, IgM)	352, <b>3000</b>	34; 35.
Epstein Barr Virus antibody against (IgG)	3100, 31001	35.
Erythrocyte sedimentation	240, 2401	31.
Erythrocytes (RBC)	171; 211, 613S	27; 29.
Estradiol	196, 196P; 196PT, 198, 198P, 199	23; 24.
Estriol (total, free)	196, 196P; 196PT, 198, 198P; <b>298</b>	23; 24; 26.
Ethanol	700, 780	26.
Ethosuximide	195	23.
Extractable nuclear antigens (ENA)	251	36.
<b>Ferritin</b>	196, 196P; 196PT, 199; 241, 241P	23; 24; 25.
Fibrinogen	222	30.
Folic acid	199	24.
Fraction COHb	162	23.
Fraction MethHb	162	23.
Fraction O <sub>2</sub> Hb	162	23.
Fructosamine	146	22.
FSH	196, 196P; 196PT, 198, 198P, 199	23; 24.
FT3	196, 196P; 196PT, 198P, 199; 294	23; 24; 25.
FT4	196, 196P; 196PT, 198P, 199; 294	23; 24; 25.
FTA-antibodies	311	35.
Fungus strain identification	412, 4121	35.
FV R534Q	740	31.
<b>G20210A mutation</b>	746	32.
Gamma globulin	1001, 100; 141	20; 21.
Gamma-GT	1001, 100	20.
Gastrin	196, 196P; 196PT, 198, 198P	23; 24.
Gentamicin	195, <b>1951</b> , 196, 196P; 196PT	23; 24.
GLDH	1001, 100	20.
Glomerular basement membrane (GBM) antibodies	257	37.
Glucose	1001, 100; 111	20; 21.
Glucose	171, 173; 161, 800	27; 28.
GOT/ASAT	1001, 100	20.
GPT/ALAT	1001, 100	20.

<b>Analytes</b>	<b>Scheme no.</b>	<b>Page</b>
Haematocrit (centrifugated, PCV)	211	29.
Haematocrit (electronic/automated)	211, 613S	29.
Haemoglobin	131; 211, 613S	21; 29.
Haemoglobin A1	145; 146, 1451+1481	21; 22.
Haemoglobin A1C	145; 146, 1451+1481; 147	21; 22; 27.
Haptoglobin	241, 241P	25.
HbA2	148, 1481, 1451+1481	22.
HbC	148, 1481, 1451+1481	22.
HBcAb	344; 3456	33; 34.
HBeAb	3456	34.
HbF	148, 1481, 1451+1481	22.
HbS	148, 1481, 1451+1481	22.
HbsAg	344; 3456	33; 34.
HCG (total)	196, 196P; 196PT, 198, 198P, 199	23; 24.
"	292; 298; 171	25; 2601 27.
HCG (free $\beta$ -chain)	298	26.
HCG (total+ $\beta$ )	196, 196P; 196PT, 198, 198P; 292	23; 24; 25.
HDL-Cholesterol	1001, 100; 151	20; 21.
HE4	199; 292	24; 25.
<i>Helicobacter pylori</i> antibodies – IgA, IgG	334	33.
<i>Helicobacter pylori</i> IgG	3100, 31001	35.
Hemopexin	241, 241P	25.
HER2	292	25.
Herpes simplex virus type 1 and 2 (IgG and IgM)	<b>3000</b> , 3100, 31001	35.
Heterophile antibodies (Paul Bunnel)	352	34.
HFE C282Y	741	32.
HFE H63D	741	32.
HFE S65C	741	32.
HGH	196, 196P; 196PT, 198, 198P, 199	23; 24.
High sensitive CRP	244; 762	22; 28.
HIV 1/2	3456	34.
Homocysteine	199; 760	24; 22.
hs-CRP	244; 762	22; 28.
Hu antibody	265	37.
Human DNA fragment(s)	730	31.
<b>IgA</b>	1001, 100; 241, 241P	20; 25.
IgE, total	1001; 196, 196P; 196PT	20; 23; 24.
"	198, 198P, 199; 241, 241P	24; 25.
IgF-I	199	24.
IgG	1001, 100; 241, 241P	20; 25.
IgM	1001, 100; 241, 241P	20; 25.
Imipramine	196, 196P; 196PT	23; 24.
Immunoblot	311	35.
INR	286; 221	28; 30.

<b>Analytes</b>	<b>Scheme no.</b>	<b>Page</b>
Insulin	196, 196P; 196PT, 198, 198P, 199; 293	23; 24; 25.
Insulin Like Growth Factor 1 (IGF-I)	293	25.
Interpretation	148, 1481, 1451+1481	22.
"	171, 173	27.
"	295; 320, 321, 322, 323	25; 26.
"	251-275	36-38.
"	3100, 31001; 452	35; 36.
"	334	33.
"	346; 351	33; 34.
Iron	1001, 100	20.
Irregular antibody screening	231, 2311	31.
<b>Jo-1</b> antibodies against	251	36.
<b>Kell</b> antigen	231, 2311	31.
Ketone bodies	171	27.
<b>Lactate</b>	1001, 100; 161	20; 28.
LAP	100	20.
LDH	1001, 100	20.
LDL-Cholesterol	1001; 151	20; 21.
Leiden mutation	740	31.
Leucocyte types in % and absolute value	212, 613S	29.
Leucocytes (WBC)	171; 211, 613S	27; 29.
LH	196, 196P; 196PT, 198, 198P, 199	23; 24.
Lipase	1001, 100	20.
Lithium	1001, 100; 195, <b>1951</b> , 196, 196P; 196PT	20; 23; 24.
LKM antibodies	253	37.
Lp(a)	151	21.
LSD	178	27.
<b>Magnesium</b>	1001, 100; 161; 173	20; 28; 27.
MCH	211, 613S	29.
MCHC	211, 613S	29.
MCV	211, 613S	29.
MDMA (Ecstasy)	178	27.
Mentzer-index	211, 613S	29.
Methamphetamine	178	27.
MetHb fraction	162	23.
Methotrexate	195	23.
Methylmalonic Acid	199	24.
Methylphenidate	178	27.
Microalbuminuria	173	27.
Microscopic sediment examination	171, 172	27.
Mid cells (Eo, Baso, Mono) in % and absolute value	613S	29.
Mitochondrial antibodies (AMA)	253	37.


<b>Analytes</b>	<b>Scheme no.</b>	<b>Page</b>
Morphine (quantitative, qualitative)	178	27.
Morphology of erythrocytes	212	29.
Morphology of leucocytes	212	29.
Morphology of platelets	212	29.
MPO	257	37.
MPV	211, 613S	29.
MTHFR C677T and A1298C	747	32.
Myoglobin	199; 760; 762	24; 22; 28.
<b>Nitrite</b>	171	27.
Nontreponemal antigene antibodies	311	35.
Nortriptyline	196, 196P; 196PT	23; 24.
NSE	292	25.
NT-pro BNP	199; 760; 762	24; 22; 28.
<b>O<sub>2</sub>Hb fraction</b>	162	23.
Onko-neural antibodies: Hu, Ri, You	265	37.
Opiates	178	27.
Osmolality	1001, 100; 173	20; 27.
Osteocalcin	293	25.
O-Streptolysin – qualitative, quantitative	321	26.
Oxycodone	178	27.
<b>pANCA (IIFT)</b>	<b>257</b>	37.
Pancreatic amylase	1001, 100	20.
PAP (Prostatic Acid Phosphatase)	199	24.
PAPP-A	298	26.
Paracetamol	195	23.
Parathyroid Hormone (PTH)	293	25.
pCO <sub>2</sub>	161	28.
pH	171; 161	27; 28.
Phenobarbital	195, <b>1951</b> , 196, 196P; 196PT	23; 24.
Phencyclidine Tricyclic antidepressivs (TCA)*	178	27.
Phentanyl	178	27.
Phenytoin	195, <b>1951</b> , 196, 196P; 196PT	23; 24.
Phosphate	1001, 100; 173	20; 27.
Phospholipids	151	21.
Platelet count	211, 613S	29.
pO <sub>2</sub>	161	28.
Potassium	1001, 100; 161; 173	20; 28; 27.
Pr3-ANCA (proteinase3)	257	37.
Prealbumin	241, 241P	25.
Pregabalin	178	27.
Primidone	195, <b>1951</b> , 196, 196P; 196PT	23; 24.
Procalcitonin	293; 320	25; 26.
Progesterone	196, 196P; 196PT, 198, 198P, 199	23; 24.

<b>Analytes</b>	<b>Scheme no.</b>	<b>Page</b>
Prolactin	196, 196P; 196PT, 198, 198P, 199	23; 24.
Propranolol	196, 196P; 196PT	23; 24.
Protein C	225	30.
Protein fractions	100	20.
Protein S	225	30.
Protein, total	1001, 100; 141; 171, 173	20; 21; 27.
Prothrombin mutation	746	32.
Prothrombin time (PT)	221	30.
PSA (total, free, complex)	196PT, 199; 292	24; 25.
PTH (Parathyroid Hormone)	293	25.
PTH Biointact	196, 196P; 196PT, 198, 198P; 293	23; 24; 25.
PTH Intact	196, 196P; 196PT, 198, 198P; 293	23; 24; 25.
<b>Quinidine</b>	196, 196P; 196PT	23; 24.
<b>RBC in the sediment</b>	171	27.
Reticulocyte count	215, 216	30.
RDW-CV	211, 613S	29.
RDW-SD	211, 613S	29.
Rh system: D antigen	231, 2311	31.
Rheumatoid factor	241P; 323, 325	25; 26.
Rheumatoid factors	273	37.
Rh-phenotyping	231, 2311	31.
Ri antibody	265	37.
ROMA	292	25.
RPR	311, 3100, 31001	35.
Rubella virus (IgG and IgM)	<b>3000</b> , 3100, 31001	35.
<b>S100</b>	292	25.
Salicylate	195, <b>1951</b> , 196, 196P; 196PT	23; 24.
SARS-CoV-2 virus	3400, 3401; 3402	34; 35.
SCC	292	25.
Scl-70 topoisomerase	251	36.
SHBG	199	25.
Sm	251	36.
Sm-RNP	251	36.
Smooth muscles antibodies	253	37.
Sodium	1001, 100; 161; 173	20; 28; 27.
Soluble transferrin receptor (sTfR)	241, 241P	25.
Specific gravity	171	27.
SS-A (Ro52)	251	36.
SS-A (Ro60)	251	36.
SS-A (total)	251	36.
SS-B	251	36.
Streptococcus, A antigen detection	321P	28.
Streptodornase – qualitative, quantitative	321	26.
Streptokinase – qualitative, quantitative	321	26.

<b>Analytes</b>	<b>Scheme no.</b>	<b>Page</b>
Syphilis Rapid Plasma Reagin (RPR), IgG	3100, 31001	35.
<b>T3</b> (free, total)	196, 196P; 196PT, 198P, 199; 294	23; 24; 25.
T3-Uptake	196, 196P; 196PT, 198P, 199; 294	23; 24; 25.
T4 (free, total)	196, 196P; 196PT, 198P, 199; 294	23; 24; 25.
T-uptake	196, 196P; 196PT, 198P, 199; 294	23; 24; 25.
Testosterone (free)	196, 196P; 196PT, 198, 198P	23; 24.
Testosterone (total)	196, 196P; 196PT, 198, 198P, 199	23; 24.
Theophylline	195, <b>1951</b> , 196, 196P; 196PT	23; 24.
Thrombin time (TT)	222	30.
Thyreoglobuline	196, 196P; 196PT, 198P, 199; 292	23; 24; 25.
TIBC (Total Iron-Binding Capacity)	1001, 100	20.
TI-rate	222	30.
Tissue transglutaminase IgA antibodies	271	37.
Tissue transglutaminase IgG antibodies	271	37.
Tobramycin	195, <b>1951</b> , 196, 196P; 196PT	23; 24.
Total haemoglobin	162	23.
Toxoplasma gondii antibody against IgG, IgM	<b>3000</b> , 3100, 31001	35.
Toxoplasma gondii antibody against IgG, IgM, IgA	452	36.
TPA	292	25.
TPHA	311	35.
TPPA	311	35.
TPS	292	25.
TRAK/THYBIA (Antibody against TSH receptor)	295	25.
Tramadol	178	27.
Transferrin	1001, 100; 241, 241P	20; 25.
Treponema pallidum (IgG and RPR)	3100, 31001	35.
Treponema pallidum antibodies	311	35.
Tricyclic antidepressants (TCA)*	178	27.
Triglycerides	1001, 100; 151	20; 21.
Troponin-I	199; 760; 762	24; 22; 28.
Troponin-T	199; 760; 762	24; 22; 28.
TSH	196, 196P; 196PT, 198, 198P, 199; 294	23; 24; 25.
<b>TSI/TSAB</b>	<b>295</b>	<b>25.</b>
<b>U1-snRNP</b>	251	36.
<b>UIBC (Unsaturated Iron Binding Capacity)</b>	<b>1001, 100;</b>	<b>20.</b>
Urea	1001, 100; 173	20; 27.
Uric acid	1001, 100; 173	20; 27.
Urobilinogen	171	27.
<b>Valproic acid</b>	195, <b>1951</b> , 196, 196P; 196PT	23; 24.
Vancomycine	195, <b>1951</b> , 196, 196P; 196PT	23; 24.
Varicella-zoster virus (VZV)	3100, 31001	35.
VDRL	311	35.
Vitamin B12 (Cobalamine)	196, 196P; 196PT	23; 24.

<b><i>Analytes</i></b>	<b><i>Scheme no.</i></b>	<b><i>Page</i></b>
Vitamin D 25-OH	196; 198; 293	23; 24; 25.
Vitamin D3 (1,25-(OH)2)	293	25.
<b>WBC in the sediment</b>	171	27.
<b>Yo antibody</b>	<b>265</b>	<b>37.</b>
<b>Zinc</b>	<b>1001</b>	<b>20.</b>

***Notes***



**The  
QualiCont  
Nonprofit Kft.  
organises**

**SARS-CoV-2 schemes:**

**3400. Virus nucleic acid determination:  
SARS-CoV-2**

**3401. POCT: SARS-CoV-2**

**3402. Virus serology: SARS-CoV-2**

*Details are on page 34-35.*

**Continuous professional  
support,  
possibility for consultation!**



**Proficiency Testing Provider Organisation  
ACCREDITED**

**by NAH (National Accreditation Authority)  
under the NAH-8-0002/2018 registration number.**



**POCT**

**Extra  
analytics**

**Molecular  
biology**

**Microbiology,  
Serology**

**Autoimmune  
serology**

**H-6720 Szeged, Feketesas u. 19-21.**

**Tel: +3662 543016; +3630 4625864**

**E-mail: [mail@qualicont.com](mailto:mail@qualicont.com)**

**Web: [www.qualicont.com](http://www.qualicont.com)**